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PRESERVING HUMAN POTENTIAL AS
FREEDOM: A FRAMEWORK FOR
REGULATING EPIGENETIC HARMS
Fazal Khan, MD., J.D.t
ABSTRACT
Epigenetics is a rapidly evolving scientific field of inquiry ex-
amining how a wide range of environmental, social, and nutri-
tional exposures can dramatically control how genes are ex-
pressed without changing the underlying DNA. Research has
demonstrated that epigenetics plays a large role in human de-
velopment and in disease causation. In a sense, epigenetics
blurs the distinction between "nature" and "nurture" as expe-
riences (nurture) become a part of intrinsic biology (nature).
Remarkably, some epigenetic modifications are durable
across generations, meaning that exposures from our grandpa-
rents' generation might affect our health now, even if we have
not experienced the same exposures. In the same vein, cur-
rent exposures could affect the health of not only individuals
currently living but also future generations. Given the relative
novelty of epigenetics research and the multifactorial nature
of human development and disease causation, it is unlikely
that conclusive proof can be established showing that particu-
lar exposures lead to epigenetic risks that manifest into specif-
ic conditions. Using the Capabilities Approach ("CA") de-
veloped by Amartya Sen and Martha Nussbaum, this article
I Fazal R. Khan is Assistant Professor of Law at the University of Georgia
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Jonathan Todres, Christian Turner, and Leslie Wolf provided very helpful comments.
Kristin Tessman provided valuable research assistance. Research funding for this
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argues that epigenetic risk is not merely a medical issue, but
that it more generally implicates the underlying fairness and
justice of our social contract. For instance, how we develop
mentally or physically has a tremendous impact upon our in-
herent capabilities and our set of life options. The CA
prompts us to ask questions such as: (1) what impact do par-
ticular epigenetic risks have on our ability to exercise free
choices; (2) are these risks avoidable; and (3) how are these
risks distributed across society? Due to the complex nature of
epigenetic risk, tort law is predictably incapable of addressing
this harm. Further, while regulatory agencies possess the sta-
tutory authority to begin addressing epigenetic harms, current-
ly these agencies are not attuned to measure or to respond to
this type of harm. This article argues that it is imperative to
initiate a regulatory framework to address epigenetic risk
from specific substances even if conclusive proof of disease
causation cannot be established. Shifting the burden of gene-
rating epigenetic risk data to producers of suspected harmful
substances serves as a start. As information concerning epi-
genetic risks accrues, the regulatory response should evolve
concurrently. As part of a dynamic policy-making approach
our goals need to encompass the following: (i) promotion of
knowledge in the scientific, legal, and public domains; (ii) as-
sessment and modification of current regulations to address
preventable risk; and (iii) an overarching commitment to pro-
tect human capabilities in an equitable manner.
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CONCLUSION
INTRODUCTION
Do our ancestors' experiences from several generations ago play a
role in our current health? Could a famine or a period of food abun-
dance experienced by our grandfathers influence whether some of us
are currently obese or likely to develop diabetes? Can being the
grandchildren of those who suffered through the threat of genocide or
intense racial discrimination affect levels of certain chemicals in our
brains even if we are not exposed to the same social stresses? In other
words, are we biologically fettered to the "memories" of past genera-
tions independent of changes to our ancestors' DNA - that is, our
human genome?
Surprisingly, according to rapidly growing research in the area of
epigenetics, the answer to all of the questions above is converging on
2612010]
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yes.' Therefore, an individual's diet, environmental exposures, and
social interactions could influence the health and behavior of that in-
dividual's offspring. The implications of epigenetics are far-ranging
and can alter the way we think about policies as widely divergent as
product safety, environmental regulation, and even affirmative action.
In a profound way, epigenetics challenges the notion that genetics
predominantly determine a person's fate and will make many of us
reconsider what we think we know about human capabilities and
predispositions. 2
As explained below, although epigenetics may predict baffling
hereditary effects, the science behind epigenetics is not incomprehens-
ible. Ultimately the greater challenge to policymakers will be to
decide whether regulations designed to avoid such harms should even
be attempted? In the face of any potential health risks, harms may
arise from inaction as well as from regulatory inaction.3
Given that our understanding of the science behind epigenetics is
still relatively new, the conservative approach might be to advocate a
"hands-off' regulatory attitude until scientific data conclusively de-
monstrates disease causation through this process. However, in the
face of initial compelling evidence that the repercussions of serious
1 See Matthew W. Gillman, Developmental Origins of Health and Disease,
353 NEw ENG. J. MED. 1848, 1848 (2005) ("At first glance, it may seem implausible
that your mother's exposure to stress or toxins while she was pregnant with you, how
she fed you when you were an infant, or how fast you grew during childhood can
determine your risk for chronic disease as an adult. Mounting evidence, however,
indicates that events occurring in the earliest stages of human development - even
before birth - may influence the occurrence of diabetes, cardiovascular disease, asth-
ma, cancers, osteoporosis, and neuropsychiatric disorders.").
2 For instance, see RICHARD J. HERRNSTEIN & CHARLES MURRAY, THE BELL
CURVE: INTELLIGENCE AND CLASS STRUCTURE IN AMERICAN LIFE (1994), which ar-
gues that intelligence is predetermined by genetics and in turn is the major cause of
socioeconomic success. Accordingly, Herrnstein and Murray conclude that dispari-
ties in socioeconomic measures such as income, crime rates, and academic success
between classes and races are genetic in origin rather than environmental. Under such
logic, social welfare policies such as affirmative action are exercises in futility be-
cause poverty in genetic endowment are to blame for group disparities, not structural
inequities or discrimination.
For example, mandating that everyone over the age of thirty has a full-
body scan might be seen as a protective health policy that would increase the early
detection of cancer. However, in addition to the direct cost of such a mandate, such a
rule might generate many false positives and needlessly expose many people to inva-
sive tests and procedures that carry serious health risks. Doctors call tumors discov-
ered in the absence of clinical symptoms or suspicion "incidentalomas." See Claudia
D. Furtado et al., Whole-Body CT Screening: Spectrum of Findings and Recommen-
dations in 1192 Patients, 237 RADIOLOGY 385, 392 (2005) (estimating that thirty-
seven percent of people who receive a full body CT scan may have abnormal findings
that need further work up).
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harm to human health could span several generations, we cannot af-
ford to take a laissez-faire approach. Further complicating our calcu-
lus is the likelihood, supported by recent research, that some epigenet-
ic modifications may be reversible.4 So how do we proceed in the
face of uncertain, but grave, harms that may or may not be reversi-
ble?
Currently, the two dominant paradigms for shaping governmental
response to public safety threats are cost-benefit analysis and the
precautionary principle.6 Cost-benefit analysis requires that the quan-
tified benefits of a proposed regulation exceed or "justify" the quanti-
fied costs. 7 However, if the risk of a threat is uncertain and therefore
unquantifiable, cost-benefit analysis provides little guidance, except
perhaps to do nothing in the absence of quantifiable justification. In
contrast, the precautionary principle holds that when an activity raises
threats to human health, precautionary steps should be taken even if
cause and effect has not been fully established. These two paradigms
are often pitted against one another and perceived in cultural and po-
litical terms.8 Cost-benefit analysis is often seen as more libertarian
4 See Moshe Szyf et al., The Social Environment and the Epigenome, 49
ENvTL. & MOLECULAR MUTAGENESIS 46, 46 (2008) ("Epigenetic programming of
gene expression is stable and long-term but yet reversible and responsive.").
We have to keep in mind that while some epigenetic marks may be revers-
ible, their effects may be irreversible depending on when they occur during an indi-
vidual's life-cycle. For instance, if a certain epigenetic mark affects early childhood
physical or mental development, reversing that epigenetic mark later in adult life will
not undo the developmental changes that have already occurred. In contrast, if a
certain epigenetic mark conveys an increased risk of late-onset disease, reversing that
mark in early adulthood could dramatically alter that individual's disease risk. See,
e.g., Genevibve P. Delcuve et al., Epigenetic Control, 214 J. CELLULAR PHYSIOLOGY
243, 243-50 (2009).
6 See, e.g., United Nations Conference on Environment and Development,
Rio de Janeiro, Braz., June 3-14, 1992, Rio Declaration on Environment and Devel-
opment, 115, U.N. Doc A/CONF.151/26 (Aug. 12, 1992) (stating the best known
formulation of the "Precautionary Principle": "In order to protect the environment, the
precautionary approach shall be widely applied by States according to their capabili-
ties. Where there are threats of serious or irreversible damage, lack of full scientific
certainty shall not be used as a reason for postponing cost-effective measures to pre-
vent environmental degradation.").
See John D. Graham, Saving Lives Through Administrative Law and Eco-
nomics, 157 U. PA. L. REv. 395, 432-34 (2008) (describing "hard" and "soft" cost-
benefit analysis).
8 Cass Sunstein has recognized that:
It has become standard to say that, with respect to risks, Europe and the
United States can be distinguished along a single axis: Europe accepts the
Precautionary Principle, and the United States does not. On this view, Eu-
ropeans attempt to build a "margin of safety" into public decisions, taking
care to protect citizens against risks that cannot be established with certain-
2632010]
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and as representing an "American way" of thinking about risk, while
the precautionary principle is cast as more paternalistic and "Euro-
pean."9 Of course, these are general characterizations of the decision-
making models, and they are not mutually exclusive, as many models
in actual use combine elements of both cost-benefit analysis and the
precautionary approach.'o
Regarding the causation of human diseases from substance expo-
sures in particular, our knowledge of epigenetics is likely to be very
fluid over the next several decades. Further, in speaking with re-
searchers in the field and reviewing the scientific literature, it is evi-
dent that the medical and scientific community generally believes that
epigenetic theory is valid and that research in this area will likely shed
much light on disease causation." However, the status quo of current
legal rules and regulatory policies do not seem to provide adequate
protection to the public from epigenetic harms. The tort system in
theory can regulate harmful substances in the stream of commerce by
imposing liability on products that cause too much harm. However,
for a variety of reasons explained below, tort law appears incapable of
limiting epigenetic risk. In addition, while the Food and Drug Admin-
istration and Environmental Protection Agency possess adequate sta-
tutory authority, their historical and current regulatory postures are not
attuned to regulating epigenetic harms.
ty. By contrast, Americans are reluctant to take precautions, requiring clear
evidence of harm in order to justify regulation. These claims seem plausi-
ble in light of the fact that the United States appears comparatively uncon-
cerned about the risks associated with global warming and the genetic
modification of food; in those contexts, Europeans favor precautions, whe-
reas Americans seem to require something akin to proof of danger.
Cass R. Sunstein, Precautions Against What? The Availability Heuristic and Cross-
Cultural Risk Perception, 57 ALA. L. REV. 75, 76 (2005).
' See id.
1o See generally Graham, supra note 7, at 432-34 (discussing a cost-benefit
approach); Holly Doremus, Precaution, Science, and Learning While Doing in Natu-
ral Resource Management, 82 WASH. L. REV. 547, 550 (2007). The hybridization of
both cost-benefit analysis and the precautionary approach is especially prevalent in
the area of climate change and environmental regulations where the costs of regula-
tion are typically more defined than the putative benefits, not allowing for a strict
balancing of costs and benefits. Doremus, supra, at 551.
" For this proposition, the author acknowledges the expert opinions of Dr.
Mark Farmer, Chair of Cell Biology Department at the University of Georgia (UGA),
Dr. Richard Meagher, Professor of Genetics at UGA, and Dr. John McDonald,
Professor of Genetics at the Georgia Institute of Technology. Further, a search of the
National Institutes of Health's PubMed database using the keywords "epigenetics"
and "cancer" during the last five years returns nearly seven thousand hits. See Nat'l
Inst. of Health, PubMed, http://www.ncbi.nim.nih.gov/pubmed (last visited May 3,
2010).
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This article proposes a dynamic regulatory framework allowing
for decisive actions against epigenetic threats without conclusive
proof of harm, but requiring continual adaptation as new learning be-
comes available. My initial claim is that available evidence regarding
epigenetic pathways of disease is sufficient to justify significant gov-
ernment funding of basic scientific research in this area. However,
implementing societal protections from epigenetic harms cannot wait
until research provides "conclusive" findings. The rationale for such
action comes from applying the Capabilities Approach ("CA") norma-
tive framework, as developed by Amartya Sen and Martha Nussbaum.
Namely, it is government's responsibility to address preventable
harms that potentially limit a person's innate capabilities and life
options. 12  Therefore, I assert that for certain suspect classes of
substances, regulation should shift the burden to producers to force
acknowledgement of the epigenetic effects of their products and activ-
ities. Going forward, in response to new learning about general epi-
genetics and specific substances, an epigenetic regulatory agency can
modulate the intensity of regulations accordingly.' 3  The different
levels of regulation include: (a) information disclosure, (b) labeling
requirements, (c) epigenetic taxes, and (d) restricted uses and bans on
certain substances.
Section I describes the science of epigenetics and how it pro-
foundly changes the scientific community's previous understanding of
heredity, environmental exposures, and disease causation. Section II
discusses how the tort system is generally incapable of addressing
epigenetic claims. Section III addresses how the American regulatory
system for harmful exposures has the potential to address epigenetic
harms but cannot perform this function effectively under its current
12 The "Capabilities Approach" (CA) developed by Amartya Sen and Martha
Nussbaum, is a normative framework that focuses on what people are actually able to
do and become from a holistic perspective, encompassing the material, political, and
social. See Martha C. Nussbaum, Forward: Constitutions and Capabilities: "Percep-
tion " Against Lofty Formalism, 121 HARV. L. REv. 4,25 (2007).
13 As discussed below, initially this organization may just be a working
group that coordinates between EPA (Environmental Protection Agency), FDA (Food
and Drug Administration), and OflRA (Office of Information and Regulatory Affairs)
to implement epigenetic regulations, as opposed to an entirely new agency. Justice
Stephen Breyer has famously proposed an agency comprised of interdisciplinary,
neutral experts who would generate risk-assessments and policy recommendations
insulated from public hysteria and special-interest groups. See Graham, supra note 7
(noting that the Institute of Medicine of the National Academy of Sciences, has used
such an organizational framework to provide expert assistance for many controversial
science and health issues such as Agent-Orange, breast implant, and vaccine injury
litigation). However, the IOM works outside the framework of government and does
not have the type of agency authority envisioned by Breyer or my proposal.
2652010]
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scheme of knowledge generation and its assessment of "unproven"
risks. Section IV discusses the normative framework of the Capabili-
ties Approach and how focusing on protecting human capabilities can
provide guidance to regulatory agencies on what interventions should
be taken with respect to epigenetic harm. Section V examines the
challenge of regulating epigenetic risks in the face of uncertainty.
Finally, Section VI outlines an adaptive regulatory framework to pro-
tect human capabilities that can modulate the intensity of regulations
as we learn more about particular epigenetic harms.
I. SCIENCE OF EPIGENETICS: OUT WITH THE NEW,
IN WITH THE OLD?
The hereditary theory of adaptation, as elucidated by Aristotle1 4
and most famously by French biologist Jean-Baptiste Lamarck," held
that the physiological changes acquired over the life of an organism
(such as a giraffe stretching its neck to reach the top of a tree or a
watchmaker developing fine motor skills) are transmitted to that or-
ganism's offspring. The scientific community firmly rejected the
concept of inheriting acquired characteristics after the acceptance of
Charles Darwin's theory of evolution and Gregor Mendel's work on
gene-based inheritance. The conclusive rejection was apparently pro-
vided by Watson and Crick's discovery of DNA, which provided
physical evidence of gene-based inheritance.' 6
Classic genetic theory holds that one's DNA sequence contains
genes that code for proteins which in turn determine a person's bio-
logical fate. Therefore, under this concept, a future generation's bio-
logical fate is determined largely by its ancestors' DNA sequences
and not at all by their ancestors' experiences. The only exception, of
course, is if an organism's exposure, to say radiation or a mutagenic
chemical, changes the underlying DNA sequence, and that altered
sequence then gets passed on to offspring.' 7 However, as the Human
14 ARISTOTLE, HISTORIA ANIMALIUM (A.L. Peck trans., Harvard Univ. Press
1965) (350 B.C.); ARISTOTLE, GENERATION OF ANIMALS (A. L. Peck trans., Harvard
Univ. Press 1963).
IS JEAN-BAPTISTE LAMARCK, PHILOSOPHIE ZOOLOGIQUE (1984); JEAN-
BAPTISTE LAMARCK, HISTOIRE NATURELLES DES ANIMAUX SANS VERTEBRES (G.P.
DeShayes & H. Milne Edwards eds., 2d ed. 1835).
6 Four nucleotides, adenine, cytosine, guanine, and thymine (symbolized as
"A, C, G, "') comprise the DNA (deoxyribonucleic acid) code. The specific order of
these four nucleotides (e.g., A-A-T-G-C-A) code for different gene products which in
turn produce different traits such as hair texture, body types, and inherited diseases.
17 See WASH. STATE DEP'T OF HEALTH, GENETIC EFFECTS AND BIRTH
DEFECTS FROM RADIATION EXPOSURE, http://www.doh.wa.gov/Hanford/publications/
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Genome Project came to fruition, scientists realized that this massive
effort of mapping out all of the human genes would provide less
answers than they hoped. The total number of genes this project dis-
covered was less than one-third of what geneticists expected given
diversity of observable traits (phenotypes).'8 Mapping human DNA
did not turn out to be a Rosetta Stone unlocking the mysteries of
heredity and disease; it was evident that a tremendous amount of bio-
logical code existed outside of the human genome. Further, if it is
supposed that DNA primarily accounts for the diversity among differ-
ent biological species, then how can genetics explain that modem
humans have ninety-nine percent of their genes in common with
puffer fish and Tyrannosaurus rex?l 9 Also, given that all of the cells
in the human body contain the exact same DNA, where does "addi-
tional" information originate that instructs one cell to develop into
brain tissue and another cell to become liver tissue?20 Finally, perhaps
the most gaping hole in classic genetic theory is that despite identical
DNA sequences, how can "monozygotic twins or cloned animals [. . .]
have different phenotypes and different susceptibilities to a dis-
ease?" 21 Gradually, scientists reconsidered the previously discarded
notion that the biological code individuals inherit involves more than
just reshuffled genes from our ancestors - thus the advent of epigenet-
ics.
Epigenetics literally means "outside of genetics" and can be de-
fined as "heritable changes in gene expression that are not due to
,,22 otew
any alteration in the DNA sequence. In other words, epigenetic
changes do not mutate or change the genetic code nor do they alter
overview/genetic.html (last visited May 3, 2010).
18 At the outset of the Human Genome Project, researchers expected to dis-
cover at least 100,000 genes in the human body. However, they found a fraction of
this number - less than 30,000. Elizabeth Pennisi, A Low Number Wins the Gene
Sweep Pool, 300 SCIENCE 1484, 1484 (2003).
1 See Margaret G. Kidwell & Damon Lisch, Transposable Elements as
Sources of Variation in Animals and Plants, 94 PROC. NAT'L ACAD. ScL. U.S. 7704,
7704 (1997) (explaining that differential epigenetic programming of extremely simi-
lar genomes seems to account for most of the physical differences among plants and
animals).
20 Differential epigenetic programming of the exact same DNA within an
organism explains organ differentiation. In other words, the precursor of a brain cell
has certain parts of its DNA turned on and other parts turned off so that eventually it
may form a neuron. Likewise, a precursor of a fat cell would have different parts of
its DNA activated ultimately to form a fat cell.
21 Manel Esteller, Molecular Origins of Cancer: Epigenetics in Cancer, 358
NEw ENG. J. MED. 1148, 1148 (2008).
22 id.
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gene products.23 Dramatic variation in cell morphology (e.g., brain v.
fat cell) and species (e.g., human v. T. rex) can be explained by highly
variable gene expression in terms of quantity of protein products
manufactured and the timing of such expression during physical de-
velopment.2 4
Several different types of epigenetic markers have been identi-
fied.25 The best known marker is DNA methylation, which involves
the binding of a methyl group to the DNA base cytosine to form
methyl-cytosine. 26 This modification has the effect of muting the ex-
pression of the surrounding DNA code. If enough cytosine bases are
methylated in a key area of a gene called the promoter region, the
gene can effectively be shut off. Epigenetic modifications can also
occur at the chromosomal level. A chromosome is an organized struc-
ture of DNA and histone proteins - collectively, the DNA and these
binding proteins are called chromatin. Binding of methyl or acetyl
molecules to histone proteins can either "loosen up" a chromosome to
form euchromatin, which will have active areas of DNA transcription,
or such binding can make parts of the chromosome more tightly
wound to form heterochromatin, which becomes inactive. Imagine a
chromosome as a long magnetic tape of information that is tightly
23 Here is a quick primer on human gene expression: (1) double stranded
DNA in the nucleus has to be separated; (2) transcription occurs when the separated
DNA strand is converted into mRNA; (3) mRNA leaves the nucleus and goes to
ribosomes in the cytoplasm; (4) ribosomes translate the mRNA into a series of amino
acids; and (5) the string of amino acids folds into a protein. Thus, most genes contain
information to make functional protein molecules (a few genes code for molecules
that aid the cell in assembling proteins).
24 See Wolf Reik, Stability and Flexibility of Epigenetic Gene Regulation in
Mammalian Development, 447 NATURE 425 (2007) ("Development is, by definition,
epigenetic. Differences in the programmes of gene expression that result in the de-
velopment of different organs and tissues occur without changes to the sequence of
our DNA (with one or two exceptions). There is nothing mysterious in this concept;
subsets of the ~30,000 genes in our genome are active in different tissues and organs,
depending on their regulation by different sets or combinations of transcription fac-
tors. This implies that if we were to take all of the transcription factors that activate
genes in a liver cell and transfer them to a brain cell (while inactivating all brain-
specific transcription factors), then the brain cell would turn into a liver cell.").
25 See id. ("During the early stages of development, genes that are required
later in development are transiently held in a repressed state by histone modifications,
which are highly flexible and easily reversed when expression of these genes is
needed. During differentiation, genes that are crucial for pluripotency are silenced by
histone modifications, as well as by DNA methylation. Some of these genes are also
silent in mature germ cells, meaning that epigenetic marks probably need to be re-
versed rapidly after fertilization to allow re-expression of pluripotency-associated
genes in the next generation.").
26 Methyl, CH3, is a small molecule. It forms methyl-cytosine after binding
to cytosine nucleotide bases.
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coiled around many tiny beads (histones). If the tape is tightly wound,
it cannot be read or transcribed. However, if a loop of tape is
unwound, the information can be accessed and transcribed. Several
other epigenetic controls have been identified, and they all act in a
similar fashion, subtly affecting or altogether blocking the transcrip-
tion of DNA. 27
The collection of these epigenetic chemical marks on the DNA
and histone proteins forms what is called the epigenome. Some have
analogized that our DNA is like computer hardware, and epigenetic
marks act as software instructing the DNA how and when to operate.
For example, if you merely possess a gene that codes for disease X, it
is not certain that you will develop disease X, as an epigenetic marker
on top of this deleterious gene can switch the gene off. Conversely,
an epigenetic marker can switch off a helpful tumor-suppressing gene
(i.e., a cancer-fighting gene) in an individual's body and thus increase
that individual's susceptibility to cancer. In terms of persistence
across generations, the genome has been characterized as "ink" and
the epigenome as "pencil":
The sequence of the four nucleotides of the genetic code is
like an indelible ink that, with rare exceptions, is faithfully
transcribed from cell to cell and from generation to genera-
tion. But on top of this code lies another one, literally "epige-
netic," which is represented by methyl groups added to the
DNA base cytosine, as well as covalent changes in histone
proteins around which DNA is coiled. This epigenetic infor-
mation is more like a code written in pencil in the margins
around the DNA. Although the genome largely distinguishes
one person from another, the epigenome, or epigenetic infor-
mation, distinguishes one cell type from another, changing ra-
pidly in early embryogenesis as cells differentiate. Mistakes
that may arise during this process are thought to be erased in
the same germ line . . . [however] this eraser may leave
smudges, potentially allowing disease to be transmitted epi-
genetically as well as genetically. 2 8
27 These other epigenetic controls include: (1) remodeling of other chroma-
tin-associated proteins; (2) transposition or "jumping" of stretches of the DNA se-
quence itself; and (3) RNA interference, where RNA molecules produced from the
DNA code bind back to the DNA.
28 Roger G. Gosden & Andrew P. Feinburg, Genetics and Epigenetics -
Nature's Pen-and-Pencil Set, 356 NEw ENG. J. MED. 731, 731 (2007).
2010] 269
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Therefore, the mechanism of epigenetic traits being passed on to
subsequent generations appears to be dependent upon epigenetic
marks being incompletely "erased" or else being erased but then
added again during critical periods of germ cell (i.e., sperm and ova)
development:
On rare occasions, however, epigenetic marks are carried over
from a previous generation ... [and] the inherited characteris-
tic has evidently been caused by incompletely erased epige-
netic marks .... Reprogramming occurs at different times in
testes and ovaries, and there may be corresponding differenc-
es in the vulnerability of targets of epigenetic modifications
.... The female germ cell may be more vulnerable to envi-
ronmental damage because . . . [t]he chromatin of growing
oocytes has a more open configuration than that of male germ
cells. 29
Is there a plausible evolutionary rationale for what appears to be a
highly variable phenomenon? Given that an individual is most sus-
ceptible to epigenetic modifications during early stages of fetal and
childhood development, one credible hypothesis is that this process
allows an organism to "take a sample" of its environmental conditions
while still developing and then to adjust the expression of its genetic
code accordingly. Since DNA is highly conservative across many
generations, epigenetic variability allows for more adaptability on a
shorter time scale. Imagine if an embryo is genetically predisposed to
be physically large, but the mother is suffering through a famine dur-
ing fetal development. The DNA code cannot adjust to this reality,
but the epigenome can - thus, the epigenome can alter gene expres-
sion to make the individual smaller and more capable of surviving in a
low-resource environment. This response appears to be a useful adap-
tation for survival of a species. However, given that epigenetic marks
can last for several generations, a rapid increase in the quantity and
29 See id. at 731-32 ("The epigenome is not permanent but undergoes dra-
matic changes at specific stages during development until it achieves more stability in
differentiated cells. Since the epigenome affects gene activity, errors can lead to
abortive development, birth defects, and cancer. A critical period for epigenetic mod-
ification extends from the time when migrating primordial germ cells arrive in the
embryonic gonad until post-fertilization stages . . . . Most methylation marks are
erased from imprinted genes in primordial germ cells of both sexes, but they are re-
placed at different stages of development in a sex-specific pattern. In men, the marks
reappear in prospermatogonia, before the cells have reentered mitosis. By contrast,
epigenetic changes in women are delayed until after meiosis has been initiated and the
oocytes have started growing in follicles, which occurs mainly after birth.").
270 HEAL TH AM TRIX [Vol. 20:259
HeinOnline  -- 20 Health Matrix 270 2010
PRESERVING HUMAN POTENTIAL AS FREEDOM
energy-profile (high fat and calorie) of the food supply, as we have
seen in nearly all countries, can lead to a population with an epige-
nome maladapted to current conditions.3 0
The following section briefly covers animal and human findings
that demonstrate the existence and effect of epigenetic marks. How-
ever, before discussing those studies, as a matter of scientific history,
it is important to note a resurgence of Lamarckism that ended in ig-
nominy. Trofim Lysenko (1898-1976) was a poorly trained agronom-
ist who improbably became the Soviet's top biologist under Stalin.3
Lysenko's "peasant-intuition" and rejection of orthodox genetics
dove-tailed with Stalinist ideology that human nature and biology are
not predetermined, but extremely malleable. 32 This notion supported
the Stalinist theory that the state could fashion "new men" if it applied
the right conditions.33 With the staunch support of Stalin, Lysenko
purged Soviet scientists (sometimes fatally) who advocated
Mendelian views. Specifically, Lysenko claimed that treating seeds to
cold temperatures ("vernalism") could improve seed and crop yields
in cold climates for several generations of plantings. 34 However, his
claims of increased agricultural production could not be replicated,
and after many years of disastrous crop yields, Soviet scientists re-
jected Lysenko as a fraud during Kruschev's tenure.35 Do recent stu-
dies mean that Lysenko, one of the great villains in science history,
has now been vindicated by the acceptance of epigenetic inheritance?
Not really. Modern epigenetics does not reject the existence of gene-
based inheritance, but posits that there is another layer of acquired
information that contributes to and modifies heredity. In essence,
Lysenko's theory of acquired inheritance was far from complete.
A. Proof of Concept: Evidence of Epigenetic Mechanisms
A search within the online medical journal database PubMed us-
ing the search terms "genetics and cancer" would return 40,704 hits
for the period of 1980-1990. In contrast, a search for "epigenetics and
cancer" during this same time period would reveal forty-three hits.36
Although epigenetics was a known factor in some diseases involving
"parental imprinting," there was almost no understanding of epigenet-
30 See Christian Nordqvist, Obesity Is a Global Epidemic, MED. NEWS
TODAY, Sept. 3, 2006, http://www.medicalnewstoday.com/articles/51123.php.
31 See DAVID JORAVSKY, THE LYSENKO AFFAIR (1970).
32 See id
33 See id.
34 See id.
35 See id
3 See Nat'1 Inst. of Health, supra note 11.
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ic markings capable of turning genes on and off in a general fashion.
The generally accepted cancer causation model is that organisms
possess different genetic predispositions and that certain triggers, such
as viral or chemical exposures, activate these underlying susceptibili-
ties. With a few rare exceptions, the notion that non-genetic factors
could be inherited and could lead to disease causation was simply not
on the research community's radar." With the growth of new re-
search discoveries, this prevailing belief has changed. A search on
"epigenetics and cancer" on PubMed now would return over 6,300
31hits for the past five years. In other words, epigenetics is no longer a
fringe area of research in the medical-scientific community.
The formulation of groundbreaking theoretical and empirical
work in this area should be credited to Dr. Randy Jirtle, a cancer re-
searcher at Duke University.39 He developed an elegant research
model demonstrating the operation of epigenetic mechanisms. He
began with agouti mice, so named because they contain a mutation for
the agouti gene.40 Expression of this deleterious gene in agouti mice
causes obesity, yellow fur, increased susceptibility to cancer and di-
abetes, and a dramatically shortened lifespan.4 1 Because the agouti
gene is dominant, breeding two of these mice together invariably re-
sults in offspring having the noticeable agouti physical characteristics
of being sickly, yellow, and obese.4 2 However, Jirtle was able to
breed two agouti mice together whose offspring were healthy, thin,
and mousy brown.43 More importantly, these offspring did not pos-
sess their parents' propensity to develop cancer and diabetes or to
have a decreased lifespan. 4 Jirtle successfully silenced the effect of
the agouti gene.
Did Jirtle engage in genetic engineering and change the underly-
ing DNA code? No. The offspring's DNA still contained the agouti
3 Courts have recognized that DES (diethylstilbestrol) ingestion by pregnant
mothers led to vaginal adenocarcinoma and other deformities in female offspring.
Because the ingestion occurred during pregnancy, the cases were explained as a case
of fetal toxicity. However, in most cases, courts have barred third generation DES
claims (granddaughters of women who ingested DES). It will be interesting to see if
these claims are brought again under an epigenetic theory.
38 See Nat'I Inst. of Health, supra note 11.
3 Robert A. Waterland & Randy L. Jirtle, Transposable Elements: Targets
for Early Nutritional Effects of Epigenetic Gene Regulation, 23 MOLECULAR &
CELLULAR BIOLOGY 5293, 5293 (2003).
40 id.
41 id.
42 id.
43 Id at 5294-96.
4 Id. at 5296.
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gene of their parents with the harmful DNA sequence intact.45 Jirtle's
intervention was surprisingly much simpler than genetic engineering -
he merely changed the mothers' diets.46 Right before conception, the
test group of maternal mice was fed a folate rich diet filled with
methyl-donorS47 which are molecules that are common in foods such
as onion, garlic, and beets. As the pregnant mothers followed this
diet, the methyl-donor molecules passed into the developing embryos'
DNA code and specifically onto the agouti gene.48 The harmful gene
was passed onto the offspring unchanged, except that the gene now
contained a chemical dimmer switch that blocked its expression. 4 9
Incredibly, these beneficial epigenetic changes were passed on to sub-
sequent generations of offspring, even in the absence of a folate rich
diet.o
As expected, additional studies have demonstrated harmful epige-
netic markings enduring multiple generations. For instance, another
rodent study found that harmful epigenetic changes related to toxic
fungicide or pesticide exposure can persist in rat offspring for at least
four generations, even though subsequent generations were not ex-
posed to these harmful chemicals. 1  In a series of infant rat studies
examining cortisol release and coping responses, researchers demon-
strated that epigenetic markings could change in response to parental
care.52 Rat pups who were licked by their mother displayed more
assertive social behaviors and, when startled, were able to calm down
more quickly than pups who were not so soothed by their mother.53
The neglected pups, on the other hand, developed into passive adults
who reacted nervously when startled or placed in unfamiliar settings. 54
These "licked rats" developed epigenetic markers that removed
"dimmer switches" located on a gene that regulates cortisol release.
In a sense, the licked rats had a better developed "stress thermostat,"
which translated into the rats being less anxious and more capable of
45 Id. at 5294.
46 Id.
47 id.
48 Id. at 5298.
49 Id. at 5296-97.
'o Id. at 5299-300.S Matthew D. Anway & Michael K. Skinner, Epigenetic Transgenerational
Actions ofEndocrine Disruptors, 147 ENDOCRINOLOGY S43 (2006).
52 Randy L. Jirtle & Michael K. Skinner, Environmental Epigenomics and
Disease Susceptibility, 8 NATURE REV. GENETICS 253, 258 (2007); Craig A. Cooney,
Epigenetics - DNA-Based Mirror of Our Environment?, 23 DISEASE MARKERS 121,
128 (2007).
5 Cooney, supra note 52, at 127-28.
54 id.
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coping in stressful situations.ss The neglected rats did not develop
this regulatory gene to the same extent, thus these rats suffered from
an overproduction of cortisol in response to stress, thereby amplifying
their anxiety. These changes were stable throughout adulthood in
the rats. Thus, the mother's nurturing behavior did not simply affect
her offspring's behavior; it physiologically altered the functioning of
the stress regulation gene inside the brain.58 But mice are not men - is
the same mechanism seen in humans?
B. Evidence of Epigenetic Mechanisms in Human Studies
Although human studies showing cause and effect for diseases
through epigenetic mechanisms are much more difficult to design and
ethically perform (humans cannot be isolated from confounding expo-
sures in labs over a lifetime or several generations like mice), epide-
miological studies focused on epigenetics are uncovering intriguing
findings. In 2005, European researchers presented a study examining
two centuries of crop yields and food prices for a geographically iso-
lated town in Northern Sweden.59 The researchers discovered that
fluctuations in the locality's food supply influenced health outcomes
spanning at least two generations. Specifically, grandfathers who
lived their pre-adolescent years during times of bountiful food supply
were more likely to have grandsons with diabetes - doubling these
grandsons' risk of early death. In other words, abundant availability
of food was demonstrated to be bad for future generations. Further,
grandsons of grandfathers who experienced plenitude during the pre-
pubescent "slow-growth" period of sperm development were the most
affected.60 Therefore, the timing of when an exposure occurs relative
to an ancestor's stage of development is crucially important for future
generations' physical development.
Compelling evidence suggests that epigenetics plays a significant
role in human mental development. Combining epigenetics with neu-
ropsychology, Canadian researchers examined the brains of men who
committed suicide after suffering physical, sexual, mental, or a com-
bination of all three types of abuse as children.6' The researchers
s See id at 127.
56 id.
* Id58 id
5 Marcus E. Pembrey et al., Sex-Specific, Male-Line Transgenerational
Responses in Human, 14 EUR. J. HUM. GENETICS 159 (2006).
60 Id.
61 Patrick 0. McGowan et al., Epigenetic Regulation of the Glucocorticoid
Receptor in Human Brain Associates with Childhood Abuse, 12 NATURE
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found that childhood abuse alters the typical chemical marking of
DNA in the brain.62 Compared with men who also suffered abuse but
died of natural causes, the suicidal men possessed decreased function-
ing in the gene that regulates the release of the stress hormone corti-
sol. 63 These findings are analogous to the previously mentioned study
of the neglected rat pups that were also not able to regulate their corti-
sol release effectively. The researchers speculated that the men's
brains were hardwired to insufficiently cope with stress as adults,
which thereby contributed to their suicides." Based on growing re-
search, scientists are concluding that childhood abuse instigates an
epigenetic response that alters the molecular structure of the develop-
ing brain.65
Moreover, maternal exposures have been the focus of many recent
epigenetic studies. For example, in the urban, low-income, minority
communities of New York City, the asthma rate is twenty-five percent
greater than the national average.6 6 A recent study has found a poten-
tial epigenetic explanation for this anomaly.67  Polycyclic aromatic
hydrocarbons (PAHs) are released from the burning of fossil fuels and
reach higher ambient concentrations in heavy-traffic, inner-city areas.
This study found that prenatal exposure to PAHs is associated with a
higher risk of childhood asthma.68 As the researchers explained:
Developmental plasticity allows the fetus to make anticipato-
ry responses to the external environment . . . . However, a
pronounced mismatch between "anticipatory adaptations"
made during early life and demands in later life could be a
cause of disease. More importantly, environmental insults
could "mislead" early organogenesis resulting in serious ail-
ments in later life . . . . This body of research suggests that
transplacental exposure to high levels of airborne PAHs could
NEUROSCIENCE 342 (2009).
62 Id. at 345.
63 Id. at 342.
64 Id. at 345-46.
65 Id. at 346.
66 Frederica Perera et al., Relation of DNA Methylation of 5'-CpG Island of
ACSL3 to Transplacental Exposure to Airborne Polycyclic Aromatic Hydrocarbons
and Childhood Asthma, 4 PLoS ONE e4488, e4488 (2009).
67 Id. ("Finally, the current finding of a putative epigenetic marker that is
associated with PAH exposure and asthma adds to other evidence from the CCCEH
cohort that PAHs increase risk of respiratory symptoms and probable asthma.").
68 Id.
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cause aberrant DNA methylation changes, leading to dysregu-
lation of gene expression and perhaps childhood asthma.69
A study examining maternal intake of fish (with low mercury content)
found that increased intake is correlated with higher cognitive test
scores for her children. 70 Another study found the higher the mother's
calcium intake, the lower her child's blood pressure.7 Paradoxically,
although maternal smoking during pregnancy is associated with re-
duced fetal growth, it also associated with an increased risk of obesity
for offspring. 72 While the associations found in these studies are not
conclusive proof of cause and effect, their implications are very sig-
nificant. As one researcher noted, "[i]f you have a generation of poor
people who suffer from bad nutrition, it may take two or three genera-
tions for that population to recover from that hardship and reach its
full potential."7 3 Although it is outside the scope of this article, going
forward it seems inevitable that governmental policies intended to
reduce socio-economic gaps, such as Affirmative Action, will have to
address the possibility that structural discrimination may cause multi-
generational harms that persist long after visible signifiers of discrim-
ination have been overcome (e.g., an African-American being elected
president).74
II. TORT LAW'S INABILITY TO ADDRESS
EPIGENETIC HARM
How should epigenetic risk be regulated in society? Some
sources of epigenetic risk (violence, discrimination, etc.) are so dif-
fuse and complex that these risks are obviously not amenable to regu-
lation by the tort system. 75 However, if an epigenetic risk factor can
69 Id.
70 Pennisi, supra note 18, at 1484.
71 Matthew W. Gillman et al., Maternal Calcium Intake and Offspring Blood
Pressure, I 10 CIRCULATION 1990 (2004).
72 A. M. Toschke et al., Early Intrauterine Exposure to Tobacco-Inhaled
Products and Obesity, 158 AM. J. EPIDEMIOLOGY 1068, 1069-70 (2003).
7 Ethan Watters, DNA is Not Destiny, DISCOVER, Nov. 11, 2006, at 32 (quot-
ing Dr. Lawrence Harper of University of California at Davis).
74 The debate regarding Affirmative Action has heated up again following
the election of President Barack Obama. Some question whether this policy is needed
after an African-American has been elected president. Joseph Williams & Matt
Negrin, Affirmative Action Foes Point to Obama: Say Candidate is Proof Effort No
Longer Needed, BOSTON GLOBE, Mar. 18, 2008, at Al. The implication of epigenetic
research is that the harms of structural racism might persist long after official sources
of discrimination have largely been dismantled.
75 As discussed in the Introduction, preliminary epigenetic research impli-
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be traced back to a particular consumer good or manufacturing activi-
ty, assigning liability through the tort system appears feasible. Thus,
private actors could use the courts to regulate epigenetic risk in the
same way the legal system utilizes products liability and environmen-
tal toxic torts to deter harmful products and activities. A hypothetical
epigenetic tort claim asserted against water bottle manufacturers that
sold bottles containing bisphenol A (BPA) can demonstrate how the
tort system might address a typical claim alleging epigenetic harm.
During the past decade or so, people frequently consumed beve-
rages from BPA-containing bottles. However, because of well-
publicized health concerns, consumers shied away from these bottles,
and manufacturers like Nalgene voluntarily came out with a BPA-free
line of bottles. BPA has been shown to cause harmful epigenetic ef-
fects in many animal studies, especially to mice that were exposed in
utero to BPA-tainted food.7 6 BPA mimics the female hormone estro-
gen, and studies have demonstrated BPA's ability to remove methyla-
tion marks, resulting in genes being turned on at the wrong time or in
the wrong tissue during crucial periods of development. In animal
studies, BPA exposure has been implicated in breast cancer,77 prostate
cancer, 78 diabetes type II,79 abnormal brain structure and behavior,8 0
cates various exposures, from environmental, nutritional, to societal, that can cause
epigenetic markings. See, e.g., Rachel Yehuda et al., Transgenerational Effects of
Posttraumatic Stress Disorder in Babies of Mothers Exposed to the World Trade
Center Attacks During Pregnancy, 90 J. CLINICAL ENDOCRINOLOGY & METABOLISM
4115 (2005) (discussing the relationship between PTSD symptoms in mothers and
infants of mothers directly exposed to the World Trade Center collapse on September
11 during pregnancy). For example, stress associated with discrimination or social
strife (e.g., being a refugee, living in a warzone) can cause epigenetic modification of
stress hormone genes. This article, however, will limit its particular focus to epige-
netic harm caused by external substances (whether natural or synthetic) and manufac-
turing activities, as these exposures are most amenable to direct regulation. I plan to
address other sources of epigenetic harm in future articles.
76 Janet Roloff, More Troubling News About BPA: Animal Studies Link
Bisphenol A with New Adverse Health Effects, SCIENCENEWS, June 12, 2009,
http://www.sciencenews.org/view/generic/id/44577/title/Science %2B-the Public_
More troubling news aboutBPA.
n T.J. Murray et al., Induction of Mammary Gland Ductal Hyperplasias and
Carcinoma in situ Following Fetal Bisphenol a Exposure, 23 REPROD. TOXICOLOGY
383 (2007).
78 Shuk-Mei Ho et al., Developmental Exposure to Estradiol and Bisphenol
A Increases Susceptibility to Prostate Carcinogenesis and Epigenetically Regulates
Phosphodiesterase Type 4 Variant 4, 66 CANCER RES. 5624, 5624 (2006).
79 Paloma Alonso-Magdalena et al., The Estrogenic Effect of Bisphenol A
Disrupts Pancreatic B-Cell Function In Vivo and Induces Insulin Resistance, 114
ENVTL. HEALTH PERSP. 106, 106 (2006).
80 Kazuhiko Kubo et al., Low Dose Effects of Bisphenol A on Sexual Diffe-
rentiation of the Brain and Behavior in Rats, 45 NEUROSCIENCE RES. 345, 354 (2003).
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accelerating puberty,8' and obesity. 82 Could these studies form the
foundation for a successful tort claim against BPA manufacturers by
someone who is able to demonstrate exposure to BPA in their blood-
stream and one of the harms listed above? For multiple reasons,
including difficulties with rules of evidence, statutes of limitations,
statutes of repose, and common law issues of fairness and justice, the
tort system would not be capable of addressing epigenetic risks and
harms emanating from BPA and other similar substances.
A. Latency Problem
By definition, with latent diseases there is a passage of time be-
tween the harmful exposure and the manifestation of disease. The
longer the latency period, the more difficult it becomes to accurately
identify to which product one was exposed many years ago. The
problem of latency arises in other toxic torts such as asbestos, but with
epigenetic claims, the biological model posits that latent harm can
persist several generations, so qualitatively speaking, latency is a dif-
ferent beast than even traditional long-tail tort problems such as asbes-
tos exposure. BPA has been used in commercial products for over
fifty years, so if the plaintiff is constructing an epigenetic claim, how
can she be sure that the harmful exposure occurred during her lifetime
and not her mother or grandmother's lifetime? One might counter
that "marketplace liability," as in asbsestos and dietheylstilbestrol
(DES) cases, can rescue claims from the problem of uncertainty in
product identification. However, as discussed below, in an era of
globalization and exponential growth in consumer goods, capturing all
of the manufacturers of BPA in a lawsuit would be nearly impossible.
1. Statutes of Limitations / Repose
When dealing with latent diseases, statutes of limitations and re-
pose also erect a difficult barrier for potential epigenetic tort claims.
Statutes of limitations for tort claims are statements by legislatures
that the time period for bringing certain kinds of claims is limited.
8 Kembra L. Howdeshell et al., Exposure to Bisphenol A Advances Puberty,
401 NATURE 763, 763 (1999).
82 id
83 In these cases, courts have imposed liability on a particular industry in
total, and the various manufacturers within this industry then have to compensate
victims in proportion to their market share of the offending product. For instance, if
defendant Acme Corp. produced twenty-five percent of the asbestos on the market
and a plaintiff X won a $100,000 lawsuit for asbestos-related injuries, then Acme
Corp. would have to pay plaintiff X $25,000 of the lawsuit award based on its market
share. See Sindell v. Abbott Labs., 607 P.2d 924, 938 (Cal. 1980).
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Underlying these laws is the idea of repose: a potential defendant
should not be chained down with the threat of indefinite liability.8 4
Typically, the statute of limitations for a tort claim starts to run at the
time of the defendant's alleged wrongful act. When act and injury
coincide (e.g. hunting accident), the policy of repose can be enforced
without causing injustice by extinguishing valid claims that may re-
main hidden. However, the problem with epigenetic claims, as with
many toxic tort claims, is that the injury underlying the claim will
very rarely manifest or be apparent within the statutory time limit.
First, the epigenetic harm might not manifest itself for many years, if
not generations, after the harmful exposure occurs. Second, many of
the diseases thought to be related to epigenetic harms, such as cancer,
have long latency periods and do not become clinically apparent until
after many years or decades. Thus, the time lag between the tortious
action and the harm makes it difficult to understand how a potential
victim of epigenetic harm could sue within the statute of limitations.
One might counter that the "discovery rule," which allows for the
tolling of the limitations period for equitable reasons until the plaintiff
reasonably should have realized or discovered the cause of her injury,
can salvage these claims. However, many jurisdictions have a statute
of repose in addition to a statute of limitations. A statute of repose
bars legal claims after a set period of time has run from the occurrence
of some event apart from the injury which gave rise to the legal
action. For instance, in the products liability context, many statutes of
repose run from the time of delivery or sale of a product. Thus, in the
case where an epigenetic insult does not cause injury until many years
or several generations later, a statute of repose could bar an epigenetic
claim before it even accrues.
2. Product Identification
Suppose a mother intends to bring a claim on behalf of a child
suffering from developmental defects linked to BPA exposure. Addi-
tionally, assume that the mother can prove that she only used one par-
ticular brand of plastic water bottle for the last twenty years at the
gym and at the workplace and is now bringing a claim on behalf of a
child who is suffering from developmental defects allegedly linked to
BPA exposure. Does this plaintiff have a viable claim? Even with
these hypothetical facts, product identification would still be a major
hurdle for this plaintiff.
84 Palma J. Strand, The Inapplicability of Traditional Tort Analysis to Envi-
ronmental Risks: The Example of Toxic Waste Pollution Victim Compensation, 35
STAN. L. REv. 575, 580 (1983).
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The Centers for Disease Control and Prevention estimates that
over ninety percent of Americans have measurable levels of BPA in
their urine. However, the market penetration of BPA-containing
water bottles is not ninety percent, so how is that possible? It has to
do with the ubiquity of BPA in many household products and the my-
86
riad pathways of exposure. Most people do not realize that BPA is
embedded in many consumer goods including the lining of metal food
cans, baby bottles and toys, cavity-fillings in dentistry, microwave
ovenware, eating utensils, flooring, enamels, varnishes, water main
filters, and many other products. 87 Further, would product identifica-
tion require tracking down what BPA-containing products her
parents and grandparents used?88 What one might initially consider a
straightforward issue of product identification (i.e., BPA from one
manufacturer's gym bottle) becomes very complicated once one fac-
tors in all potential sources of exposures across multiple generations.
B. Multifactorial Nature of Disease Causation
A major problem with assessing tort liability for epigenetic harms
is proving causation. Plaintiffs in most tort cases have the burden to
prove their case by a preponderance of the evidence, which means
showing a greater than fifty percent probability that a particular agent
caused a harm. Given the multi-factorial genesis of most diseases that
can be ascribed to epigenetic harm, conceptually it is difficult to im-
agine more than fifty percent of the blame being assigned to a single
agent. Further, with epigenetic claims, the causal chain can be very
attenuated and indirect compared to typical toxic tort claims. For in-
stance, if the harmful exposure occurred to your grandfather and not
you, most likely there would be too many intervening variables for a
trier of fact to attribute more than fifty percent blame to any given
agent. Further, if a lab analyzed any random individual's fat tissue, it
would discover measurable levels of numerous chemicals that studies
have linked to various diseases, including the same diseases linked to
BPA. The problem is that on a global scale, human populations are
exposed to a giant stew of chemicals that are inevitably absorbed
85 CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP'T OF HEALTH &
Hum. SERVS., SPOTLIGHT ON BISPHENOL A (2009), http://www.cd c.gov/exposure
report/pdf/factsheet-bisphenol.pdf [hereinafter BISPHENOL FACTSHEET].
86 Id.
87 Sheldon Krimsky, Plastics in Our Diet: The Need for BPA Regulation
When Scientists Find Chemicals that Disrupt Human Systems, Regulators Must Ban
Them, Sci. Am., Oct. 3, 2008, available at http://www.scientificamerican.com/article
.cfmn?idlastics-in-our-diet.
See latency discussion supra Section H(A).
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within their bodies. Given these considerations, any competent de-
fense attorney likely would be able to nullify any epigenetics-based
tort claims.
C. Tort Claims for Increased Risk
Could the tort system be adjusted to take account of epigenetic
claims? As research continues, we will likely learn more about epige-
netic profiles (epigenomes) associated with increased risk of disease.
This development raises the issue of whether risk can be considered
an "injury." A basic element of personal injury torts is that the plain-
tiff must show evidence of harm in the form of a "physical injury." In
textbook personal injury cases, a harm-inducing event, whether from a
botched surgery or industrial accident, results in a readily apparent
injury. Absent a showing of injury, there is no basis for recovery.
However, considering advances in diagnostic laboratory tests which
can predict disease conditions prior to the development of clinical
symptoms, some legal commentators argue that the traditional risk-
injury dichotomy may no longer be tenable.89 This debate is especial-
ly relevant for potential epigenetic claims as scientists predict the
eventual ability to generate individual epigenetic fingerprints which
can demonstrate a causal relationship between certain exposures and
epigenetically modified diseases. The question then becomes, how
would tort law treat epigenetic marks linked to certain diseases? Are
these marks merely indicators of future risk, or do they represent ac-
tual harm compensable under the law?
While the risk-injury debate in tort policy is not new, innovative
research in the area of "biomarkers" has reinvigorated this discussion.
A biomarker is a biochemical substance or feature that can be objec-
tively measured and analyzed to indicate the presence of a normal or
pathologic biological mechanism at the molecular levels of cells.
Focusing at this level of detail has enabled researchers to identify pre-
viously undetectable "intermediate events between chemical exposure
and clinically recognizable disease." 90 Thus, epigenetic markings can
be understood as a particular type of biomarker which, in certain cas-
es, indicates a heightened risk of disease.
Under the traditional tort model, subcellular damage, or damage
that occurs at the level of DNA or genetic repair mechanisms but has
89 See Jamie A. Grodsky, Genomics and Toxic Torts: Dismantling the Risk-
Injury Divide, 59 STAN. L. REV. 1671, 1671 (2007); Albert C. Lin, Beyond Tort:
Compensating Victims of Environmental Toxic Injury, 78 S. CAL. L. REv. 1439
(2005).
90 Lin, supra note 89.
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not manifested as structural damage at the cellular level or above, is
deemed to be benign and hence legally irrelevant. 91 Alternatively, the
"diseased state" model holds that although disease might be undetect-
able using traditional techniques, it may be present and ongoing.
Therefore, the "true" latency period is shorter than what classical
medical symptoms would suggest. In other words, what medicine
once characterized as "enhanced risk" stemming from toxic exposures
can now be understood as actual "injuries" at the subclinical level.92
If this argument is accepted, then tort law would transform to regard
subcellular insults as actual physical harm instead of potential harm.
A legal implication of this change would be that the traditional tort
element of harm could now be demonstrated before the clinical
manifestation of the disease.
One can argue that courts have already shown an increasing
awareness of biological risk and latent disease processes by recogniz-
ing nontraditional claims such as "enhanced risk" and "medical moni-
toring." The basic elements of a medical monitoring claim are:
A plaintiff can recover the costs of medical monitoring if (1)
he establishes that he was significantly exposed to a proven
hazardous substance through the negligent actions of the de-
fendant; (2) as a proximate result of the exposure, the plaintiff
suffers a significantly increased risk of contracting a serious
latent disease; (3) by reason of the exposure a reasonable phy-
sician would prescribe a monitoring regime different from the
one that would have been prescribed in the absence of the ex-
posure; and (4) monitoring and testing procedures exist that
make the early detection and treatment of the disease possible
and beneficial.93
Not surprisingly, industry and the defense bar have vehemently ar-
gued that liability should only be assessed for actual injuries, not la-
tent risks. They contend that latent risk claims would fling open the
proverbial floodgates of litigation. The Supreme Court's rejection of
a medical monitoring claim under the Federal Employers Liability Act
I in Metro-North Commuter Railroad Co. v. Buckley is highly relevant
to the risk versus injury tort debate. 94 The plaintiff was exposed to
asbestos as a pipe-fitter but did not have evidence of any present in-
jury. These specific facts are relevant because it is well-established
9' Grodsky, supra note 89, at 1676.
92 See Lin, supra note 89.
9 Metro-North Commuter R.R. Co. v. Buckley, 521 U.S. 424, 450 (1997).
9 See id. at 455.
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that this type of occupational exposure is associated with future de-
velopment of mesothelioma (cancer of tissue lining the lungs).95 As a
matter of epidemiology, this relationship is not speculative or in the
"twilight zone" of medical acceptance. While the Court did not reject
the validity of medical monitoring claims as a general matter, its deci-
sion in the context of these particular facts sent a clear signal that the
Court disfavored imposing liability without evidence of harm.9 6  i-
deed, since the Metro-North decision, five state supreme courts have
considered whether to recognize medical monitoring claims without
evidence of present injury, and all five courts have declined to recog-
nize such claims. 97
It seems inconsistent that courts accept the validity of claims for
latent harms, but only if the offending exposure causes an additional
harm that has already manifested. If epidemiological evidence has
demonstrated a substantial risk between exposure and latent harm, and
evidence of sufficient harmful exposure is present, the requirement of
"present injury" should not be needed if the judiciary accepts compen-
sation for latent risks. The reality seems to be that courts are uncom-
fortable addressing issues of biological risk and require that plaintiffs
suffer demonstrable physical injury to legitimate an assignment of
liability. From a biological perspective, the concept of disease as a
spectrum rather than a binary on/off event is logical. Indeed, this
concept informs many medical protocols that focus on well-being as
opposed to just disease prevention and treatment.98  However, ab-
stracting a legal rule from this spectral disease paradigm is problemat-
ic. Logically, many people are suffering from early stages of disease
even if outwardly they feel healthy. For instance, researchers have
detected coronary atherosclerosis in many teenagers and young adults
who do not present any outward symptoms of heart disease.99 While
95 Occupational Safety & Health Admin., U.S. Dep't of Labor, Asbestos
Hazards, http://www.osha.gov/SLTC/asbestos/hazards.html (last visited May 3,
2010).
96 521 U.S. at 440-41.
9 SHAWN D. BRYANT, WASHINGTON LEGAL FOUND., FEDERAL COURT FINDS
MEDICAL MONITORING TORT UNAVAILABLE IN TEXAS (2006), http://www.wlf.org/
publishing/publication detail.asp?id=1761.
98 The World Health Organization's (WHO) definition of health captures this
concept: "Health is a state of complete physical, mental and social well-being and not
merely the absence of disease or infirmity." Preamble to the Constitution of the
World Health Organization, opened for signature July 22, 1946, 62 Stat. 2679, 14
U.N.T.S. 185.
9 E. Murat Tuzcu et al., High Prevalence of Coronary Atherosclerosis in
Asymptomatic Teenagers and Young Adults: Evidence from Intravascular Ultra-
sound, 103 CIRCULATION 2705, 2706-08 (2001).
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early atherosclerosis likely portends future heart problems, this condi-
tion is difficult to classify as an injury if it is presently causing no
symptoms or functional decline.'1 This conundrum raises the diffi-
culty of establishing thresholds for when epigenetic markers of risk
can be considered injuries in the tort sense. It seems that one would
first need to establish what a "normal" risk profile is, which may not
be possible. Thus, one is brought back full circle to the logic that a
clinically diagnosed injury must be the predicate for a medical tort
claim. o
D. Weak Deterrent Signal from Torts
As discussed above, the tort system is not capable of addressing
epigenetic harms for a variety of reasons. So what are the conse-
quences of this legal failure? In many ways, the barriers epigenetic
claims putatively face in the tort system mirror those barriers present
in environmental and toxic torts although, as discussed above, the
expected barriers for epigenetic claims would be even higher. In the
context of environmental and toxic harms, one of the primary roles the
tort system is considered to fill is a regulatory public health role.102 in
other words, the tort system sends deterrent signals to environmental
harm producers via those who are injured and legally pursue claims
against these producers. o3 However, "[e]mpirical evidence suggests
that environmental tort suits" send "a weak deterrent signal."' In
theory, a person harmed by toxic waste seeping from an industrial
factory can bring a tort claim, receive compensation for his or her
injuries, and deter future exposures. In practice, studies have shown
that such individuals are unlikely to receive tort compensation. Legal-
ly toxic waste disposal injuries are intrinsically different from the par-
ticularized, immediate harms around which tort law developed. The
lapsed time between the disposal and injury, and the inherently diffuse
nature of causation, generally act to discourage these claims. 05 In
addition, potential plaintiffs for these claims face stiff practical bar-
riers to accessing the judicial system, such as high financial costs and
'to See id. at 2708-09.
'0 Allan L. Schwartz, Annotation, Recovery of Damages for Expense of
Medical Monitoring to Detect or Prevent Future Disease or Condition, 17 A.L.R. 5th
327 (1994).
102 This primary role is in addition to compensating individuals who suffer
harm.
103 Troyer A. Brennan, Environmental Torts, 46 VAND. L. REV. 1, 2 (1993).
I04 Id.
1os Strand, supra note 84, at 575.
284 HEAL TH MA TRIX [Vol. 20:259
HeinOnline  -- 20 Health Matrix 284 2010
PRESERVING HUMAN POTENTIAL AS FREEDOM
the ability to find willing counsel. 10 6 If the deterrent signal for tradi-
tional toxic torts is weak, then we can expect the tort deterrent signal
for epigenetic harms to be minimal to non-existent.
E. Minimal Tort Incentive for Long-Term Safety Precautions
Lack of toxicological or material safety data is a problem that un-
dermines many potential toxic tort claims. However, private actors
have very little incentive to generate this data. Such defendants will
likely not invest to protect against expected harms that seem minimal
in nature and not lucrative enough for plaintiffs to pursue in litigation.
Conversely, harm producers will only invest enough research re-
sources to avoid liability from activities or products that can be
foreseen to cause extreme injuries or harm a large number of people.
Of course, the problem with this foreseeability standard is that the
general public is often not aware of what is not known. 07 Additional-
ly, even if a corporation can foresee a fairly high risk (say forty per-
cent) of financially damaging tort liability emerging thirty years into
the future, it is not clear that most corporate managers would take
action to avoid such liability. Avoiding such liability would require
corporate managers to incur a present cost to receive an indeterminate
benefit (liability avoided) that will be recognized in the future, per-
haps long after they leave the corporation. Furthermore, rewards for
short-term performance (higher share value and bonuses) mean that
incentives to minimize present costs greatly outweigh any incentive to
avoid future tort liability.
Lastly, the tort system places the burden on plaintiffs to establish
the causal link between a substance and an injury, but plaintiffs rarely
have the resources necessary to analyze existing data or to generate
new scientific results. Corporate defendants have better access to
relevant information about their products and manufacturing activi-
ties, but if these defendants are not required to generate safety data by
' Mary L. Lyndon, Tort Law and Technology, 12 YALE J. ON REG. 137, 168
(1995).
107 Secretary of Defense Donald Rumsfeld famously uttered this gem on the
subject of foreseeability, "Reports that say that something hasn't happened are always
interesting to me, because as we know, there are known knowns; there are things we
know we know. We also know there are known unknowns; that is to say we know
there are some things we do not know. But there are also unknown unknowns - the
ones we don't know we don't know." Donald H. Rumsfeld, U.S. Sec'y of Defense,
Dep't of Defense, DoD News Briefing - Secretary Rumsfeld and Gen. Myers (Feb.
12, 2002), http://www.defenselink.mil/transcripts/transcript.aspx?transcriptid= 2636.
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some regulatory body, they have little incentive to disclose or develop
risk data that can lead to liability. 08
F. The Justice Problem: Being Punished for Wrongs
Committed by Others
Assuming arguendo that one could somehow reformulate tort
rules to accommodate epigenetic claims stemming from many years
or generations past, it is not clear that one should welcome this end
based on considerations of justice and efficiency. As discussed above,
one of the major rationales for the tort system is to deter and regulate
harm in society. The other major rationale is to achieve corrective
justice between the harmed victim and the tortfeasor. This notion
stems from a conception of justice based on individual liberty. For
instance, if a corporation negligently causes injury, imposing liability
on the corporation furthers corrective justice if the group of people
represented by the corporation does not change significantly between
the time the tortious act occurred and the time the liability is im-
posed.' 09 However, if there is a substantial change in the individuals
representing the company, the imposition of corporate liability would
not further this notion of individual-based corrective justice.'' 0
The concern therefore is that imputing liability for epigenetic
harms on present-day individuals for harms caused by past actors
seems like an unfair debt to inherit. One might be tempted to retort
that the truly unfair debt to inherit is the epigenetic harm, not the tort
liability. However, this latter view would entail holding defendants to
contemporary standards of scientific knowledge, rather than what was
known at the time of their actions. If actors are unaware of harms
they cause due to lacunae in general scientific knowledge, as opposed
to willfully remaining ignorant of knowable risks, it is not fair to im-
pose judgment of wrongdoing ex post.
Efficiency considerations also argue against imposing tort liability
for long-past actions. At the margins, endeavors that reasonably
appear to be beneficial and safe might be avoided due to fear of un-
known future liability."' Further, if a manufacturer stopped produc-
ing the offending product many years ago, relaxing statute of repose
laws to account for epigenetic causation would not satisfy any deter-
rent role. Instead, such action may only serve to punish a party that
might produce entirely unrelated and highly beneficial products.
108 Strand, supra note 84.
'" Id at 605.
110 Id .
..Id at 601.
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In summary, the tort system does not seem the proper framework
to address epigenetic harms. As some have suggested in the realm of
toxic tort injuries, the only way to accommodate epigenetic legal
claims would require stretching tort standards regarding causation,
evidence, presence of physical injury, and limitations periods. How-
ever, we have to ask whether such Procrustean measures are justified
and likely to be effective. It appears that the answer to both of these
questions is negative; in using the tort system to hear epigenetic
claims, it seems that there is a trade-off between justice and effective
outcomes.
III. INADEQUACY OF CURRENT REGULATORY
REGIME TO ADDRESS EPIGENETIC HARM
As presently conceived, U.S. regulatory agencies cannot ade-
quately address epigenetic harm. For example, skin is the largest or-
gan in the human body. While our skin can protect our internal or-
gans from many environmental exposures, it is not an impermeable
barrier and many substances can pass through our skin. Hence the
efficacy of nicotine or birth control patches. Given this fact, it would
be fair for most American consumers to assume that products that
come in contact with our skin, such as cosmetics, shampoos, and other
personal care products are tested for safety by the Food and Drug
Administration (FDA). However, this assumption would be wrong.
The FDA only focuses on the safety of hair dyes and does not have
the explicit authority to regulate cosmetics.1 2 The issue of expanding
FDA authority to regulate cosmetics has been raised many times in
the Senate over the past five decades, but each time lobbyists from the
cosmetics industry have defeated such efforts. For instance, a re-
cent study conducted by a consumer protection group found that many
popular brands of lipstick sold in the United States contain measurable
amounts of lead, a known neurotoxin that is especially damaging for
the developing brain.1 4 But since the FDA does not regulate lipstick
directly, no federal guidelines govern lead content in cosmetics."'
A. Legal Authority for Public Safety Regulation
The lack of current regulation does not mean that the FDA and
Environmental Protection Agency (EPA) do not possess the legal au-
112 Don't Pucker Up: Lead In Lipstick, ABC NEWS, Oct. 12, 2007,
http://abcnews.go.com/GMA/story?id=3722013.
114 id.
115 id
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thority, under their existing statutory grants, to more closely protect
human health and the environment from unsafe foods, drugs, cosmet-
ics, consumer products, pesticides, and manufactured chemicals.
Under the Food, Drug, and Cosmetic Act (FDCA), the FDA places
the burden on pharmaceutical and medical device manufacturers to
demonstrate that their products are (i) safe and (ii) effective through
a rigorous multi-phase testing process. Similarly, under the Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA), the EPA re-
quires pesticide manufacturers to prove that their products are reason-
ably safe.'1 6 In both cases, there is no presumption of safety, and the
manufacturers bear the burden of showing that a product is safe.'"7 In
the abstract, the FDA and EPA have the power to shift the burden
onto manufacturers to demonstrate that their products do not cause
undue epigenetic harm. However, the reality is that the FDA does not
use this burden-shifting power for the vast majority of commercial
substances absorbed through human skin. As a consequence, if the
regulatory status quo is maintained, the FDA and EPA will do very
little to bridge the huge gaps in knowledge regarding the epigenetic
safety of most consumer products and chemicals. An examination of
these agencies' current efforts to regulate known or suspected toxins
bears out this dim assessment." 8
The Administrative Procedure Act (APA) governs the legality of
actions taken by federal agencies. In Chevron, the Court constructed
a two-part test for reviewing agency decisions pursuant to a statute.119
The first part is to ascertain whether Congress has already decided the
issue in question, or in other words, whether it has precluded what the
agency proposes to do. The second part is to determine whether the
agency interpretation is reasonable and not arbitrary or capricious.
116 The EPA administers the Federal Insecticide Fungicide and Rodenticide
Act (FIFRA) which is aimed at protecting people and the environment from "unrea-
sonable adverse effects." FIFRA shifts the burden onto manufacturers to prove that
their products are safe for their intended use before obtaining federal approval for
sale. Prior to marketing a new pesticide the manufacturer must provide to the EPA
health information such as "data on its acute toxicity, neurotoxicity, and potential
carcinogenicity." Nathaniel Garrett, "Life is the Risk We Cannot Refuse: " A Precau-
tionary Approach to the Toxic Risks We Can, 17 GEO. INT'L ENVTL. L. REv. 517, 545
(2005).
117 Based upon safety data pesticide manufacturers submit, the EPA then sets
what levels of human exposures are allowable. Under this burden-shifting scheme,
the presumption is that the chemical is not safe for use until the manufacturer proves
otherwise. In other words, the burden of showing that a pesticide is safe "remain[s] at
all times on the applicant and registrant." Id.
118 id.
" Chevron U.S.A., Inc. v. Natural Res. Def. Council, Inc., 467 U.S. 837
(1984).
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Therefore, generally speaking, federal agencies have broad discretion
to interpret the scope of regulatory statutes, and the courts are reluc-
tant to second-guess agency rulemaking. However, courts have not
extended this general rule to the EPA's application of the Toxic Sub-
stances Control Act (TSCA).120
Among other things, TSCA grants the EPA the authority to re-
strict the use of and mandate safety testing of suspected toxins pro-
duced by chemical companies. Thus, after its passage, TSCA was
considered a potentially powerful tool to protect against harmful ex-
posures. In 1989, after conducting a ten-year study costing millions
of dollars and amassing a 100,000 page administrative record, the
EPA announced it would phase out and ban all uses of asbestos. 12 1
The EPA's stated rationale was that "asbestos is a human carcinogen
and is one of the most hazardous substances to which humans are ex-
posed in both occupational and non-occupational settings."l 22 The
United States Court of Appeals for the Fifth Circuit overturned this
ban in Corrosion ProofFittings v. EPA, holding that the EPA failed to
present "substantial evidence" under which to justify the ban. 123 The
court found that:
[c]ontrary to the EPA's assertions, the arbitrary and capricious
standard found in the APA and the substantial evidence stan-
dard found in TSCA are different standards, even in the con-
text of an informal rulemaking . . . . Congress specifically
went out of its way to provide that "the standard of review
prescribed by paragraph (2)(E) of section 706 [of the APA]
shall not apply and the court shall hold unlawful and set aside
such rule if the court finds that the rule is not supported by
substantial evidence in the rulemaking record . . . taken as a
whole." 15 U.S.C. § 2618(c)(1)(B)(i) . . . . The substantial
evidence standard mandated by [TSCA] is generally consi-
dered to be more rigorous than the arbitrary and capricious
standard normally applied [ ].124
The court further reasoned that the EPA had failed to show that a ban
was the "least burdensome alternative" for dealing with the risk posed
120 Corrosion Proof Fittings v. EPA, 947 F.2d 1201, 1213-14 (5th Cir. 1991).
121 Asbestos; Manufacture, Importation, Processing, and Distribution in
Commerce Prohibitions, 54 Fed. Reg. 29,460, 29,461 (July 12, 1989) (to be codified
at 40 C.F.R. pt. 763).
122 Id. at 29,468.
123 947 F.2d 1201 (5th Cir. 1991).
124 Id. at 1213-14.
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by asbestos, failed to consider the cost of there not being adequate
substitute products, and improperly considered "unquantifiable bene-
fits" in its cost/benefit analysis.12 5 The EPA did not appeal this deci-
sion.
Given the significant legal and knowledge burdens the Fifth Cir-
cuit construed TSCA as requiring, this decision effectively eviscerated
the utility of this Act as a regulatory tool. Regarding safety data for
commercially produced toxins, since the passage of TSCA over three
decades ago, the EPA has promulgated testing protocols for less than
one percent of the 75,000 manufactured chemicals on its own Toxic
Substances Inventory list.126 Further, by focusing on the absence of
currently available substitutes for asbestos, the court ignored the in-
centives that "technology-forcing" regulations can place upon indus-
try to create such alternatives. It is a common American perception
that government regulation necessarily hurts innovation and economic
growth.127  Returning to the differences between European and
American regulatory attitudes, the Europeans are more comfortable in
mandating standards on industry even if such standards require the
development of technology that does not currently exist. For instance,
European regulators are far more aggressive in mandating fuel effi-
ciency standards for automakers and technology standards for cell
phone manufacturers.' 2 8 In the United States, automakers and cell
phone manufacturers resisted such regulations, arguing that the
regulations were not technically feasible and were likely to cause eco-
nomic injury to the industry.12 9 However, these technology-forcing
regulations did not harm the European auto or cell phone industry;
125 Id. at 1219.
126 Noah Sachs, Blocked Pathways: Potential Legal Responses to Endocrine
Disrupting Chemicals, 24 COLUM. J. ENVTL. L. 289, 313-14 (1999).
127 See Kimberly S. Johnson, Ford CEO Says Regulation Often Hurts Innova-
tion, ABC NEWS, June 17, 2009, http://abcnews.go.com/Business/wireStory?id
=7862126 ("Ford Motor Co. CEO Alan Mulally said government regulation in many
ways has hurt innovation among businesses and manufacturers in the United States.
'We've become so stymied with regulation,' said Mulally Wednesday during a panel
discussion on innovation in manufacturing at The National Summit in Detroit. 'We
have to say enough is enough and get back to freeing people up."').
128 Reilly Brennan, New, Stricter Fuel Standards for Cars, AOL AUTos, May
20, 2009 (announcing President Obama's new mileage and emission standards that
will require cars and trucks to meet a comprehensive 35.5-mpg standard by 2016, and
explaining that the U.S. will still lag behind Japan and Europe despite these new
standards); Telecom Firms Back Standard Phone Charger in Europe, REUTERS, June
29, 2009 ("Top mobile telephone suppliers have agreed to back an EU-wide harmoni-
zation of phone chargers, the European Commission said on Monday, hailing the pact
as good news for consumers and the environment.").
129 BRYANT, supra note 97.
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instead, by being forced to produce more efficient cars and to focus
industry efforts on one cell phone standard (GSM), European automo-
bile and cell phone makers are in better economic positions than their
American counterparts.' 30
B. Phthalates: A Case Study of Regulatory Inaction
As discussed in the previous section, BPA belongs to a class of
chemicals known as endocrine disruptors and has been implicated in
causing epigenetic harm. Phthalates are another class of chemicals
that have been identified as endocrine disruptors and might cause sim-
ilar epigenetic harm as BPA.' 3' Phthalates are used in the manufac-
ture of a variety of products, including plastic films used in food
packaging, infant toys (they make plastics soft and pliable), and
paint.132 Alarmingly, phthalates have been detected in many
processed foods such as margarine, cheese, and baby formula.'33 Stu-
dies have shown that if children suck on plastic toys that contain
phthalates, then they may experience elevated levels of this chemical.
Responding to these findings, the European Union (EU) removed
phthalates from children's toys starting almost a decade ago. In con-
trast, the United States Congress did not take action to ban phthalates
in products for children until August 2008, when it banned phthalates
in products designed for children under twelve years old. 134 Further,
this law allows retailers and manufacturers to sell off their existing
inventory of toys, plastic sip cups, and other products that contain this
chemical. Currently, there is no legal requirement to label products
containing phthalates. 35
From an epigenetic perspective, this regulation safeguarding
children under age twelve is woefully under-protective. Theoretically,
children who currently use phthalate products may pass along harmful
developmental defects to their future offspring mediated by epigenetic
130 While all automakers have been hurt by the economic downturn, it is clear
that American manufacturers have been particularly hard hit in the global marketplace
by lagging behind in making more fuel-efficient cars.
131 See generally, Liz Szabo, Toy with Phthlates Can Be Sold After U.S. Ban
Takes Effect, USA TODAY, Nov. 19, 2008, available at http://www.usatoday.com/
news/health/2008-11-19-phthalate-federalban N.htm (reporting on dangers that
phthalates in children's products pose to the hormone system); Env't & Human
Health, Inc., Plastics that May Be Harmful to Children and Reproductive Health,
http://www.ehhi.org/reports/plastics/phthalates exposures.shtml (last visited May 3,
2010).
132 Env't & Human Health, Inc., supra note 131.
133 id.
134 See Szabo, supra note 131.
135 See id.
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mechanisms. The bottom line is that without a coherent and compre-
hensive regulatory policy to quantify and control such epigenetic
harm, we cannot construct rules rationally tailored to avoid such
harms. Instead we may be saddled with policies that are reactionary,
quasi-arbitrary, and ultimately ineffectual in achieving their intended
goals.
Going forward, the question to ask is whether agencies such as the
EPA and FDA have the ability to regulate epigenetic harm emanating
from industry. Put another way, can these agencies impose practical
steps on industry such as mandatory testing, information disclosure, or
product restrictions based upon epigenetic rationales? This question
can be answered by assessing whether epigenenetic risks fall within
the bounds of risks these agencies are currently authorized to regulate.
Analogizing to examples involving asbestos and cosmetics, most like-
ly affected industries could successfully challenge the enforceability
of epigenetic-based regulations under current regulatory guidelines,
arguing that such actions are based upon unquantifiable costs and
benefits or that available data is not "substantial" enough.
Given the qualitative nature of epigenetic risks (diffuse, multi-
generational, multi-factorial, etc.), it is predictable that even as re-
searchers learn more about epigenetic risks from everyday exposures,
such risks cannot be calculated with any certainty. The consequence
is that epigenetic risks will continue to reside within a regulatory la-
cuna, and preventable harms will go unchecked as a result. The ne-
cessary response, then, is for Congress to recognize that epigenetic
harms are unique and to specifically grant authority to either a new or
existing agency (which can create a new epigenetic division) (i) to
address epigenetic harms even if they cannot be quantified under tra-
ditional regulatory formulas and (ii) to expand the scope of goods and
activities that fall under such regulation (e.g., cosmetics). The new
epigenetic regulatory agency, supported by this general statutory grant
to address epigenetic harm, can legally implement the adaptive regula-
tory framework I propose in Section VI. However, before discussing
the practical regulatory steps, the normative case for Congress chang-
ing the current administrative and regulatory rules has to be made.
Therefore, in Section IV below, I detail how the Capabilities Ap-
proach provides a compelling normative justification for addressing
epigenetic harm in particular.
IV. THE CAPABILITIES APPROACH: THE
NORMATIVE CASE TO ADDRESS EPIGENETIC HARM
The descriptive claim that I am making is that epigenetic harm is
qualitatively different from other toxic risks that regulatory agencies
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have historically perceived and addressed. An expected critique of
my view is that epigenetic harm is the same as other garden-variety
toxic risks, with the exception that it has a much longer tail, meaning
that the manifestation of harm occurs long after the causative expo-
sure. In other words, epigenetic harm is akin to the plight of a pipe
fitter who develops mesotheliomia decades after being exposed to
asbestos. I would argue that epigenetic harms are qualitatively differ-
ent than long-tail harms tort law has dealt with and thus requires a
novel way of addressing these particular harms. First, epigenetic
harm can limit ex ante an individual's human potential before that
individual is even born or conceived. This affliction can be distin-
guished from having a harmful genetic predisposition because, as dis-
cussed earlier, the relative immutability of the genetic code is a fact of
biology shared by everyone. In contrast, epigenomes are far more
mutable and susceptible to modifications caused by environmental
exposures. Second, the person taking on the risk of exposure is often
not the individual herself but an ancestor. Third, researchers have
demonstrated that epigenetic marks can have a profound impact on an
individual's mental and physical development. Thus, such develop-
mental changes will most probably exert a greater impact on an indi-
vidual's lifelong capabilities compared with a harm like mesothelioma
(a typically late-onset cancer) which would not greatly impact an in-
dividual's capabilities or freedom of life choices prior to the manife-
station of the disease. However, merely proving the case that epige-
netic harm is different than other biologically mediated harms does
not provide the policy justification for rethinking and adapting how to
regulate harmful exposures.
Compared with the two regulatory frameworks that currently pre-
dominate - cost-benefit analysis and the precautionary approach - the
"Capabilities Approach" (CA) developed by Amartya Sen and Martha
Nussbaum, provides an evaluative framework that is better adapted to
map the specific policy challenges posed by epigenetic risk. Further,
if policymakers apply the CA, it illuminates a clear normative justifi-
cation for aggressively addressing epigenetic risk - the imperative to
protect an individual's autonomy and agency. In other words, an in-
dividual's freedom to choose among alternative lives that she could
possibly lead if not fettered by preventable epigenetic burdens. The
following subsection will first describe what the CA is and the policy
directives that it generally commands. Then this section will examine
how application of the CA can articulate the need for regulatory poli-
cies specifically focused on epigenetic risk.
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A. Rawls and the Capabilities Approach
Sen and Nussbaum's development of the CA can be seen as a re-
sponse and critique, but not a repudiation, of John Rawls' famous A
Theory ofJustice. Indeed, both Sen and Nussbaum acknowledge their
debt to Rawls' work, and the CA is similar to Rawlsian theory in that
both are social contractarian and explicitly deontological rather than
consequentialist.'3 6  However, Sen and Nussbaum express concern
that Rawlsian theory fails to account for the innate diversity within
human populations and will still lead to significant injustice in socie-
ty. 137
In A Theory of Justice, the "original position" plays a central role
in Rawls' social contract conception of justice. The original position
uses the heuristic of the "veil of ignorance" to ensure unbiased judg-
ment when thinking about fundamental principles of justice. All indi-
viduals are veiled or blinded to knowledge of their personal, social,
and historical characteristics. Thus, one is unable to select
self-serving principles because one's actual status in society is un-
knowable. Rawls argues that individuals conceived of in this original
position possess two moral qualities: (i) they have a sense of fairness
and equality which compels them to look for cooperation; and (ii)
they possess the ability to form a conception of what it means to have
a good life.'3 8 Rawls concludes that rules derived from his procedural
theory of justice will lead to an equal distribution of basic liberties he
terms "primary goods."' 3 9  Sen and Nussbaum argue that Rawlsian
and other concepts of justice ignore an important element - an indi-
vidual's capacity to transform whatever is distributed to him or her
equally into something that enables that individual to live a meaning-
ful life.
136 For this reason the CA has also been described as "Kantian" in that out-
comes are irrelevant for judging whether an action or policy is "good." Utilitarianism
by contrast is explicitly consequentialist and outcome-focused.
13 Sen and Nussbaum both point out that individual's born with developmen-
tal disabilities would fare poorly under a Rawlsian distribution of primary goods as
they might require more resources to ensure the same capability set. Nussbaum,
supra note 12.
138 John Rawls, The Priority of Right and Ideas of the Good, 17 PHIL. & PUB.
AFF. 251, 258 (1988).
139 Rawls conceives of the primary goods as "a scheme of equal basic liberties
and fair opportunities, which, when guaranteed by the basic structure, ensures for all
citizens the adequate development and full exercise of their two moral powers and a
fair share of the all-purpose means essentials for the advancement of their conceptions
of the good." Id.
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B. Basic Elements of the Capabilities Approach
The CA focuses on ensuring individual autonomy and free
choice. 140 This translates into the CA asking what people are actually
capable of doing and becoming when viewed from a holistic perspec-
tive. As Nussbaum puts it, the CA's concept of capability encom-
passes the material, political, and social spheres of existence. 141 Thus,
the CA goes beyond asking whether people have "freedom" in the
legal sense; the CA inquires "to what extent people are really in a
position to avail themselves of these freedoms and it directs attention
to other areas of choice and opportunity, such as education and
healthcare."l 42 Thus, the central CA directive is that society must
provide its members with the preconditions of a dignified human life
- a core group of "capabilities" without which a person could not
choose a worthy life.143
The CA parses these capabilities from a quasi-biological perspec-
tive.'" For instance, "innate abilities" are the elementary abilities
people are born with that give them the potential to live a worthy life
characterized by being able to exercise autonomy and make free
choices. Viewing them akin to a vulnerable seedling, the CA is con-
cemed that these innate abilities might wither away and not grow into
something stronger if society does not provide adequate support to
develop these innate abilities into effective capabilities. Nussbaum
terms the developed form of innate abilities "internal capabilities." 45
The CA argues that equitable distribution of government assistance in
areas such as education, healthcare, and safety is a desideratum for
citizens to acquire "internal capabilities."l4 6 However, while internal
capabilities are necessary to live a dignified life, they are not suffi-
cient if individuals lack the liberty to freely express their capabilities
140 First, it is important to note that Nussbaum diverges from Sen in her de-
velopment of this theory, and henceforth, when referring to the CA, I am referring to
Nussbaum's particular version.
141 Nussbaum, supra note 12.
142 Id. See also AMARTY SEN, DEVELOPMENT AS FREEDOM (1999). However,
as Nussbaum points out, while both her version of CA and Sen's focus on an individ-
ual's ability to lead a dignified life and argue for the importance of government in-
vesting in areas such as education and healthcare, their versions are not the same.
When the "CA" is referred to in this paper, it is referring to the particular version
articulated by Nussbaum.
143 Nussbaum, supra note 12, at 7.
'44 Id. at 11.
145 MARTHA NUSSBAUM, WOMEN AND HUMAN DEVELOPMENT: THE
CAPABILITIES APPROACH 84-86 (2000).
146 id.
2952010]
HeinOnline  -- 20 Health Matrix 295 2010
in a functional manner.147 Thus, the CA articulates that government
must produce "combined capabilities" in its citizens, that is, "internal
capabilities combined with suitable external circumstances" that pro-
tect an individual's opportunity to pursue functions within his or her
developed capabilities set. 148 To reiterate, the CA is explicitly not
consequentialist - its goal is not to have individuals achieve some
meaningful endpoint, but rather to ensure that people have the capa-
bility to choose meaningful ends.149
The CA posits that government needs to ensure a minimum
threshold of capabilities, distributed across its citizens, to achieve a
basic minimum of justice. The CA pragmatically recognizes that is it
not possible to ensure equal capabilities above a certain minimum
threshold and is silent on these inequalities. For instance, a society
should provide for universal education and healthcare, but it cannot
possibly guarantee that everyone will pursue a university degree or be
in good physical shape. Thus, it is acceptable that people possess
adequate capabilities without possessing fully equal levels of
14 Illustrating from real-world examples how internal capabilities are not
sufficient to lead a dignified life, Nussbaum states:
People may be well educated, well fed, and healthy, however, and yet lack mea-
ningful opportunities to use their powers in action. Many people who are capa-
ble of speaking freely, in the sense that they have been educated and cultivated,
lack the meaningful opportunity to speak freely in public, because their nation
has not protected their freedom of speech, or has not protected it equally for all.
For women in many parts of the world, it has been a common experience to find
oneself full of internal capabilities that one never gets a chance to use, because
many nations have not given women political rights, property rights, rights over
their own bodies, and so forth, or have not given these rights to women and men
on a basis of equality.
NUSSBAUM, supra note 145, at 11-12.
148 Under this formulation of "combined capabilities," we can see that epige-
netic risk can be associated with both innate abilities like cognitive or physical devel-
opments and external circumstances such as gender or race discrimination or living in
a war zone.
149 Sen points out that substantive freedom has to be judged not only by the
amount of options available to an individual, but also the attractiveness of those op-
tions. See SEN, supra note 142, at 117-18. Further, Nussbaum illustrates the differ-
ence between focusing on outcomes versus the freedom to pursue certain outcomes:
[H]aving meaningful political rights (and really having them, not just as
words on paper) does not require one to participate in politics. Members of
the Old Order Amish have the right to vote, and they choose not to use it.
That is just fine. To compel them to vote would be insufficiently respectful
of their freedom. Similarly, people who have adequate nutrition available
may always choose to fast-for example, for religious reasons. There is,
however, a large difference between fasting and starving, and it is that dif-
ference that the CA wishes to capture.
Nussbaum, supra note 12, at 12.
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functioning. However, the CA is not silent on inequities that are the
products of discriminatory practices rather than inate abilities. For
instance, singling out minority neighborhoods for toxic waste dump
sites or neglecting to provide access to good schools in these neigh-
borhoods would violate CA tenets.150  Therefore, while equality of
capabilities is not the goal, equality in terms of nondiscrimination in
the cultivation of capabilities is central to the CA.
The CA differs from a utilitarian, or traditional cost-benefit,
framework in several fundamental ways. First, the CA considers each
person to be an end. This would make it impermissible for the gov-
ernment to promote the overall good in a fashion that infringes upon
the rights of individuals to lead a dignified life.' 5 1 For example, the
construction of the Three Gorges Dam in China might prove to have a
dramatic net benefit when considering its utility for the collective enti-
ty of over a billion Chinese citizens and thus would satisfy a tradition-
al cost-benefit analysis.152 But given that this project severely
upended the lives of millions of rural Chinese (without restoring the
life options available to them before the project commenced), the CA
would evaluate this project as unjust. Instead of summing the indi-
vidual benefits and costs to individuals, the CA would instead focus
on the individuals most adversely affected by this project and ask if
they still possessed the basic minimums required for a dignified life.
Another key component of the CA is that opportunities are plural and
non-commensurable. This means that vital capabilities are distinct
and cannot be converted to a generic utility value that can be summed
with other distinct capabilities to form a single net utility.'"3 For in-
stance, this means that a government cannot compensate for a paucity
of political rights by providing extremely generous housing and
healthcare entitlements.154 Lastly, the CA elevates the role of educa-
150 See generally Dorothy E. Roberts, Privatization and Punishment in the
New Age ofReprogenetics, 54 EMORY L.J. 1343 (2005).
'1 Nussbaum, supra note 12, at 14.
152 The Three Gorges Dam on the Yangtze River is estimated to provide at
least one-nineth of China's energy needs and open the rural interior of the country to
further economic development. While these net benefits might accrue to over a bil-
lion Chinese, it is estimated that at least 5.3 million Chinese will have to be resettled
as their homes become uninhabitable. Antoaneta Bezlova, China: Three Gorges Dam
May Displace Millions More, IPS NEWS, Oct. 12, 2007, available at
http://www.ipsnews.net/news.asp?idnews-3962 1.
153 d.
154 Nussbaum clarifies:
The plurality and distinctness of the ends does not mean, however, that they do
not often support one another. For example, education supports political activi-
ty, the freedom of speech, and the ability to protect one's bodily integrity from
abuse (because education gives employment options and thus exit options from
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tion and cognitive abilities because the framework considers these
capabilities as essential to fulfilling its central political goal of having
"a nation of free choosers."'s For instance, a government policy to
provide citizens with solely vocational and scientific training to the
exclusion of the humanities might produce more productive workers
who can increase societal wealth and GDP (thereby increasing net
utility), but this would not satisfy the CA.156 Meaningful choice and
options in life are not possible without an individual's ability to perce-
ive, to think, and to select among varied options and cannot be meas-
ured by gross aggregate calculations such as GDP. 1 As discussed
below in Section V, the CA's focus on innate abilities and equality of
opportunity support a stronger government response to epigenetic risk
than would a typical utilitarian, cost-benefit analysis.
Examining epigenetic risk under the CA lens, two major concerns
rise to prominence. One is the role of epigenetic harm in impairing
mental development. This matter flows from the CA focus on educa-
tion and cognitive development. Without fully developed mental fa-
culties, individuals cannot exercise meaningful life choices. The other
major concern is the potentially unequal distribution of epigenetic
harm. This type of disparity would intrinsically disadvantage certain
groups from reaching a full capabilities set. Given the CA's insis-
tence on equality of opportunity, the proscription to ensure a basic
threshold of capabilities for all citizens would be violated. Thus,
viewed from the CA framework, the problems associated with un-
checked epigenetic risk go far beyond biological and medical
concerns - the CA implicates much deeper questions of justice. The
virtue of a framework incorporating both the CA and epigenetics is
that such a framework more robustly tests the fairness of any social
contract, as compared with a pure Rawlsian approach.
an abusive marriage).
Nussbaum, supra note 12, at 14.
' Id. at 15.
156 See ALDOUs HUXLEY, BRAVE NEW WORLD (1946) (Aldous Huxley's criti-
que of a modem, technocratic society based on utilitarian principles in his dystopian
classic Brave New World parallels my argument. Huxley imagined individuals being
manufactured in birthing centers, in assembly-line fashion, to become producers and
consumers with varying utilitarian skills, but not free thinkers capable of making free
choices.).
157 Nussbaum, supra note 12, at 14.
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V. REGULATING EPIGENETIC RISK IN THE FACE OF
UNCERTAINTY
Given that researchers are still learning a great deal about epige-
netics and are far from proving causation of diseases from particular
exposures through this mechanism, how should society approach the
problem of epigenetic risk? Put in more practical terms, how do poli-
cymakers go about allocating resources or regulating the behavior of
individuals or industry regarding potential epigenetic harms? In many
ways, the problem of epigenetic risk mirrors the debate over how
to manage global climate change. First, the targeted harm is multi-
generational since current actions putatively can have dramatic effects
on third parties who have not been born. Second, while compelling
evidence is emerging that preventable human activities are contribut-
ing to or causing both kinds of harm, the scientific community has not
established conclusive proof of these relationships. Third, the effects
of regulations to protect against these harms remain uncertain. So
how should decision-makers proceed? In this regard, a rigorous eval-
uation of several different decision-making models is needed to come
up with a legitimate basis for crafting epigenetic policies. To this end,
I will briefly examine the efficacy and fairness of three different deci-
sion-making models from a CA perspective: cost-benefit analysis; the
precautionary approach; and the optimal-search method. Each mod-
el's potential strengths and weaknesses can be seen as I apply these
models to a contemporary policy debate with profound epigenetic
implications - the decision to mandate fortification of flour with folic
acid.
A. Cost-Benefit Analysis
Cost-benefit analysis is utilitarian in nature in that a policy deci-
sion or action is acceptable only when the calculated benefits are
greater than the costs.'58 It is consequentialist in that it focuses on
quantifiable outcomes rather than fairness of process. There are many
different iterations of this model, from a simple unweighted approach
that treats each individual's utility equally to a weighted approach that
gives more weight to the utility of those starting at a lower baseline. 59
However, regardless of the version, net utility has to be positive to
justify an action.
In addressing epigenetic harm in particular, the cost-benefit analy-
sis approach has two major weaknesses. First, a regulator cannot
s58 See generally Graham, supra note 7.
159 id.
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make an accurate or meaningful calculation of costs and benefits can-
not if gaps are present in the data or no proof of causation exists.
Without the ability to calculate epigenetic risk, on its own terms this
model will not guide a determination of whether a particular policy
choice is beneficial. Given the relatively new focus on the field of
epigenetics and the countless number of exposures that can cause epi-
genetic markings, it is unlikely that one will see "conclusive scientific
proof' that specific exposures definitively cause particular diseases.16 0
Second, it is difficult to conceive of an interpersonal utility measure
that adequately signifies the same degree of utility for disparate indi-
viduals. Assuming variable trade-offs and outcomes that could occur
with epigenetic interventions, finding a way to assign utilities to all of
these different outcomes that have universal and objective meaning
would be a Sisyphean task. For instance, how does one measure the
trade-off between the risk of slightly lower cognitive development
versus a slightly higher risk of colon cancer: by cost of treatment, or
by summing individual preferences between the two? Ultimately, the
cost-benefit approach places the "burden of explanation" on the regu-
latory agency to justify its policy.161 Therefore, if scientific proof is
lacking or calculating utilities for disparate outcomes is not feasible,
this model will not provide an answer. The result is that even if quali-
tatively there is evidence of grave and irreversible harm that could
justify regulation, without the quantitative data backing up regulation,
inaction is the likely result.
B. Precautionary Principle
The "precautionary principle" has emerged as the predominant
guiding principle in almost every major international environmental
and natural resource proposal or agreement.' 62 The United Nations
Rio Declaration on Environment and Development demonstrates how
the precautionary principle is applied in practice - "[w]here there are
threats of serious or irreversible damage, lack of full scientific certain-
ty shall not be used as a reason for postponing cost-effective measures
to prevent environmental degradation." 63  Some have reduced this
160 Besides the complexity of exposures that can cause epigenetic modifica-
tions, another level of complexity is variation in genetic predispositions. That is,
certain epigenetic markings or exposures almost certainly would not affect all popula-
tions equally.
161 Graham, supra note 7.
162 Garrett, supra note 116, at 519.
163 United Nations Conference on Environment and Development, Rio de
Janeiro, Braz., June 3-14, 1992, Rio Declaration on Environment and Development,
f 15, U.N. Doc A/CONF.151/26 (Aug. 12, 1992).
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principle to the motto "better safe than sorry" or have described it as
implementing a "'margin of safety' into public decisions, taking care
to protect citizens against risks that cannot be established with certain-
ty."'" The antecedent of the precautionary principle is the German
vorsorgeprinzip or "forecaring" principle. While the Germans' love
of cars and beer is legendary, so is their passion for their beloved fo-
rests which were in danger of disappearing from "acid rain." Thus, in
the 1970s, West Germany moved first to take decisive regulatory
steps to combat acid rain even though its relation to deforestation was
not empirically proven, only suspected. While varying definitions of
the precautionary principle exist, its common understanding is that as
the interactions between man-made activities and the natural world
become more complex, any decision-making model that prevents ac-
tion until conclusive scientific causation is established leaves society
vulnerable to harm. However, despite its preeminence in international
accords and its inclusion as "one of the most important ideas of 2001"
in the New York Times Magazine, the precautionary principle has been
largely rejected by Americans. 165 As Cass Sunstein states, "It has
become standard to say that, with respect to risks, Europe and the
United States can be distinguished along a single axis: Europe accepts
the Precautionary Principle, and the United States does not." 6 6
Sunstein in particular is associated with a vigorous critique of the
precautionary principle. He contends that what people tend to take
precautions against is very arbitrary and subject to certain cognitive
biases. 16 7 But perhaps more importantly, Sunstein contends that if
applied consistently as a norm, this principle is "paralyzing" and
"stands as an obstacle to regulation, and nonregulation, and to every-
thing in between."' 68 Sunstein argues that if one truly takes precau-
164 Sunstein, supra note 8.
165 id.
166 Id.
167 Cass R. Sunstein, Beyond the Precautionary Principle, 151 U. PA. L. REV.
1003 (2003). According to Sunstein, the precautionary principle is particularly sus-
ceptible to the following cognitive biases: (1) availability heuristic; (2) probability
neglect; (3) loss aversion; (4) benevolence of nature; and (5) system neglect.
168 According to Cass Sunstein:
This point makes the Precautionary Principle hard to implement, not merely
where the regulation removes "opportunity benefits" or introduces or in-
creases substitute risks, but in any case in which the regulation costs a sig-
nificant amount. If this is so, the Precautionary Principle raises doubts
about many regulations. If the principle argues against any action that car-
ries a small risk of imposing significant harm, we should be reluctant to
spend a lot of money to reduce risks, simply because those expenditures
themselves carry risks. In this sense, the Precautionary Principle, taken for
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tions against all risks, one should also be equally fearful of risks asso-
ciated with regulation.' 69 So how can the view that the precautionary
principle is inherently paralyzing be reconciled with the fact that is
has been used to justify substantial environmental and public safety
regulations in the EU? The response would be that the EU's more
intensive regulatory approach in these areas is based on the peculiar
cognitive biases of what Europeans fear, not on a principled applica-
tion of the precautionary approach.170  However, even Sunstein ac-
knowledges that experts analyze problems differently than lay people
so presumably regulatory agencies, which are data-driven and reliant
on experts, would not fall into the same trap of biased thinking as a
layperson.171  Further, it is not as if traditional cost-benefit data is ig-
nored under the precautionary approach; presumably, as new data
emerges, this information can be incorporated into the policies in-
itiated under the precautionary approach.
C. Optimal Search
While the cost-benefit approach advocates for choosing the policy
with the highest average utility, and the precautionary principle argues
for a "better safe than sorry" approach, the optimal search method,
under certain conditions, advocates selecting high-risk policies with
the potential for the best outcomes even if the average utility is lower
all that it is worth, is paralyzing: It stands as an obstacle to regulation, and
nonregulation, and to everything in between.
Sunstein, supra note 8, at 86.
169 See id.
170 For instance, Sunstein claims that the Europeans are much more concerned
about genetically modified organisms (GMO's) and hormones in meat because they
suffered through a mad-cow disease scare which was very prominent in their media
and public debate (implicating the availability heuristic), but the U.S. is not as fearful
as these products because we did not have a mad-cow scare. See id.
171 In the words of Sunstein:
Sometimes the precautionary principle has the appearance of being worka-
ble only because a subset of the relevant effects are "on-screen"-and, as a
result, there seems to be no need to take precautions against other possible
adverse effects, also involving health and safety, that do not register. An
important aspect of system neglect is tradeoff neglect, one source of the
conflict between experts and ordinary people in thinking about risks. When
experts disagree with ordinary people about risks, it is sometimes because
experts look at both the benefits and harms associated with the relevant
practice, whereas ordinary people are paying attention to the harms but the
not the benefits. I suggest that the precautionary principle seems appealing,
to ordinary people, in large part for the same reason.
Sunstein, supra note 167, at 1010.
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than less risky policies. 17 2 The primary drawbacks of this particular
recommendation are the possibility of discovering flaws after a policy
is implemented and the inability to reverse its effects. However, if a
high-risk policy fails and its effects are reversible, it can be quickly
abandoned for a policy with the highest average outcomes (i.e., less
risky) and one would not suffer any long-term consequences. But if
the high-risk policy is a success, then its benefits can be adopted and
no search is needed for an alternative plan. If policymakers choose
the low-risk policy with higher average outcomes in the first instance,
then the possibility of achieving more optimal outcomes is precluded.
After all, if the low-risk plan confers some net benefit, political inertia
would make it less likely that this plan would be abandoned for a
more risky option. To the extent a policy is irreversible, uncertainty
becomes a liability as a potentially a low-benefit outcome might be
cemented in place. In other words, the less one is able to undo the
effects of a policy, the more costly the risk becomes in one's policy
calculus. Thus, a major limitation of the optimal search framework is
that it is highly dependent on choices that are reversible and hence is
not universally applicable.
D. Applying the Three Decision Making Models to Ireland's
Folic Acid Debate
A national controversy with profound legal and ethical implica-
tions is currently raging in Ireland. Most policymakers, however, are
unaware of the epigenetic implications of this debate. Explicitly, the
policy debate focuses on whether the Irish government should
mandate the fortification of flour with folic acid. Giving folic acid to
pregnant women is a highly effective means of preventing neural tube
defects (NTDs) such as spina bifida and anencephaly in children.173
However, the folic acid must be consumed four weeks prior to con-
ception and for twelve weeks after conception to achieve this protec-
172 See generally Yair Listokin, Learning Through Policy Variation, 118
YALE L.J. 480 (2008) (arguing the utility of policy variance depends upon the reversi-
bility of the policy).
173 Spina bifida is a condition where the vertebrae do not fully form a ring
around the spinal cord, so that some of the spinal cord or its surrounding membrane
sticks out through this opening. See Nat'l Inst. of Neurological Disorders & Stroke,
Nat'l Inst. of Health, NINDS Spina Bifida Information Page (2007), http://www.ninds
.nih.gov/disorders/spina bifida/spina bifida.htm. Anencephaly is a condition where
the higher brain is not formed and only a brain stem. Most of these fetuses are still-
born or spontaneously aborted. In the case of live birth, anencephalic infants have a
very short life span typically of a few hours or days. See Nat'l Inst. of Neurological
Disorders & Stroke, Nat'l Inst. of Health, NINDS Anencephaly Information Page
(2009), http://www.ninds.nih.gov/disorders/anencephaly/anencephaly.htm.
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tive effect.17 4 In other words, giving women folic acid only after they
discover their pregnancy is akin to closing the barn door after the
horse has escaped. As it stands, Ireland has one of the highest rates of
NTDs in the developed world for several reasons. First, unlike the
United States and Canada, Ireland does not mandate that its flour
supply be fortified with folic acid. Second, a very high percentage of
pregnancies in Ireland are unplanned (fifty-five percent). And third,
elective abortions are illegal in Ireland.
In 2004, Ireland established the National Committee on Folic
Acid Fortification (NCFAF). The group was tasked with analyzing
three policy choices.'7 ' The first option presented was structured vo-
luntary fortification. In this case, flour millers and bakers would be
legally permitted to voluntarily add specified amounts of folic acid
and then carry a special logo and health claim on their product. The
second option was mandatory fortification imposed upon bakers and
flour millers. The third option was to continue with the current prac-
tice of not fortifying flour, but to engage in public health education
campaigns to urge women to take folic acid supplements and eat a
folate-rich diet.
A policy of mandating folic acid fortification demonstrably re-
duces NTDs. For instance, Newfoundland reduced its NTD rate by
seventy-eight percent after Canada (and the United States) mandated
flour fortification in 1996.176 The NCFAF also considered that, in
Ireland, formal campaigns since 1993 advising women to take folic
acid have been met with little success. In 2006, the NCFAF recom-
mended the implementation of the second option, mandatory fortifica-
tion. However, this policy recommendation has yet to be enacted by
the Food Safety Authority of Ireland (FSAI), so de facto, the third
option of maintaining the status quo is in force. Why has the FSAI
failed to act on a policy that is recommended by an expert panel and
has strong empirical evidence supporting its intended goal? Unfortu-
nately, recent studies have raised the specter that folic acid can in-
crease the risk of human cancers of the colon, breast, and prostate. As
a result, the FSAI has received considerable pushback against manda-
tory fortification from both the Irish food industry, which is concerned
174 FOOD SAFETY AUTH. OF IR., PUBLIC'S VIEWS SOUGHT ON FOLIC ACID
FORTIFICATION - FOLIC ACID TODAY AND EVERYDAY - POLICY OPTIONS BEING
CONSIDERED (Mar. 21, 2005), http://www.folicacid.ie/press/press 20050321.html.
175 FOOD SAFETY AUTH. OF IR., NATIONAL COMMITTEE ON FOLIC ACID FOOD
FORTIFICATION, http://www.folicacid.ed/nat comm.html (last visited May 3, 2010).
176 PUB. HEALTH AGENCY OF CAN., EVALUATION OF FOOD FORTIFICATION WITH
FOLIC ACID FOR THE PRIMARY PREVENTION OF NEURAL TUB DEFECTS,
http://www.phac-aspc.gc.ca/publicat/faaf/chap5-eng.php (last visited May 3, 2010).
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about liability, and consumers who are wary of the reported cancer
risk.177
In general, the studies showing a link between folic acid and can-
cer are not conclusive and indeed some studies show that folic acid
may protect against cancer. 17 8 As discussed above in Section I, folic
acid has significant epigenetic effects because it is a methyl-donor,
leading to the hypermethylation of DNA. Recalling Jirtle's mice ex-
periment, it was the mother's folate-rich diet that was responsible for
shutting off the harmful agouti gene and that shut-off then resulted in
a dramatic improvement for these mice "predestined" to die an early
death. However, does folic acid "know" only to turn off harmful
genes and to not turn off beneficial genes? Of course, there is no in-
tentionality behind this process, meaning that one can logically expect
that hypermethylation caused by folic acid might turn off beneficial
genes as well. One also has to consider that the impact of shutting
down a particular gene varies temporally within the life-cycle of an
individual.' 7 9 For example, the p53 gene is important in preventing
cancer and suppressing the growth of tumors, which it accomplishes
by activating DNA repair proteins. 80 This process of DNA repair is
more important as one ages, as DNA errors from repeated replication
or sustained environmental damage add up over a lifetime. Thus, for
preventing cancers associated with increased age, like colon, breast, or
prostate cancer, .any deactivation of the p53 gene would be a serious
problem. This effect may partially account for the correlation be-
tween folic acid consumption and cancers developed later in life.
So how should Ireland resolve this epigenetic debate? Applying
the cost-benefit model does not seem to provide an answer because
while researchers good data regarding the benefits of folic acid fortifi-
cation (reduced NTDs), the costs (i.e., increased cancer risk) are
177 See generally Claire O'Connell, Folic Acid Delay "Unreasonable", IRISH
TIMES, July 8, 2008, at Health 2 (reporting on researchers' in Ireland calling for man-
datory fortification of flour with folic acid, and the Food Safety Authority of Ireland's
position on the matter).
178 For instance, one study reported the chance of developing colorectal can-
cer was lowered by forty percent in women with the highest folate intake compared to
those with the lowest intake. See Paul Terry et al., Dietary Intake of Folic Acid and
Colorectal Cancer Risk in a Cohort of Women, 97 INT'L J. CANCER 864, 866 (2002).
179 See SCIENCEDAILY, Health Benefits, Consequences of Folic Acid Depen-
dent On Circumstances, Apr. 5, 2009, http://www.sciencedaily.com/releases/2009/04/
090401134421.htm ("Thus, folate appears to assume different guises depending on
the circumstances. The level of intake of this micronutrient that is safe for one person
may be potentially harmful to another.").
Iso Yuangang Liu & Molly Kulesz-Martin, P53 Protein at the Hub of Cellular
DNA Damage Response Pathways Through Sequence-Specific and Non-Sequence-
Specific DNA Binding, 22 CARCINOGENESIS 851, 851-60 (2001).
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uncertain and unquantifiable at the moment. Therefore, without the
ability to conduct this balancing, this model does not provide an an-
swer. Assuming hypothetically that the cancer risk from folic acid
supplementation can be quantified, policymakers would still face the
challenge of generating an interpersonally comparable utility value to
compare the risk of NTDs with the risk of cancer.'81 Does one com-
pare the financial costs of treating a child with spina bifida versus an
adult with colon cancer? Some children with spina bifida die very
young, so the overall financial cost of treatment might be lower than
someone undergoing multiple cancer treatments. Does one compare
lost productivity? If a fifty year old employed person develops colon
cancer, the loss in productivity can be great. Most children with spina
bifida have below average I.Q.'s and require special education - does
one measure their lost productivity assuming they would have average
I.Q. and be gainfully employed? Maybe the conundrum of establish-
ing interpersonally comparable value can be avoided by asking how
much money people would be willing to pay to avoid NTD or differ-
ent cancers.182 These individual subjective preferences can then be
summed up, and the policy choice with highest net benefits would be
chosen. For Irish citizens, this calculus would obviously be different
depending on whether a person is expecting to have a child. Howev-
er, the majority of pregnancies in Ireland are unplanned, and generally
speaking, an individual's desire to have children might vary greatly
during their span of reproductive years. Thus, even assuming reliable
cancer data, this model may not provide a satisfactory policy choice.
Does the precautionary approach provide better guidance for
Ireland? In this particular instance, Sunstein's critique of the precau-
tionary approach as paralyzing has some validity. If one wants to
focus on taking precautions against NTDs, then one would choose the
mandatory folic acid fortification option. But if one is more con-
cerned about taking precautions against cancer risk, then one would
181 One of the persisting critiques of utilitarian analysis is that individual
preferences are highly subjective and creating utility values that have the same mean-
ing or value to disparate individuals is impossible to accomplish.
182 See Graham, supra note 7,410-11 (Willingness to pay (WTP) and willing-
ness to accept (WTA) are used in the Kaldor-Hicks model of cost-benefit analysis:
"[Kaldor-Hicks] is implemented through the use of [WTP] money as the measure of
social benefit (B) and [WTA] money as the measure of social cost (C). If an individ-
ual expects a regulation to be beneficial to her, WTP is positive. If another individual
expects to be harmed by regulation, her WTA will be positive. Citizens who are
indifferent (or who perceive that gains equal losses) do not influence the benefit-cost
calculation. When multiple regulatory alternatives are compared, the preferred alter-
native is the one that maximizes net benefits, defined as the sum of B minus the sum
of C across all citizens in society.").
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reject this option and instead choose the voluntary fortification or the
status quo. Being generally precautious would lead to fear of both
types of harms which in turn would lead to a policy stalemate. This
scenario is what seems to be happening in Ireland, where strong op-
posing opinions have led to a non-policy for the time being.'83
As discussed above, the optimal search method argues for choos-
ing policies with a high degree of variability if the effects of the policy
can be reversed. Compelling scientific data suggests that epigenetic
markings associated with blood and solid tumor cancers can be re-
versed - this evidence has already led to FDA approval of the first
anti-cancer epigenetic drug, azacitidine.184 As one ages, cancer rates
stemming from epigenetic risk increases because of a possible excess
accumulation of folic acid in our diet, nutritional or pharmaceutical
interventions like azacitidine may reverse this risk. However, once an
individual is born with spina bifida or some other condition that im-
pairs early mental and physical development, these impairments are
mostly irreversible through epigenetics or other means.
Without any pretense of empirical precision or units, Figure 1
conceptually represents the choices Ireland faces in graphical form.
On the y-axis, welfare or benefit is formed by the sum of the risks of
NTDs and cancer stemming from a particular folic acid fortification
policy. The x-axis is time. The middle solid line represents the base-
line or the status quo policy. Given the a priori uncertainty regarding
cancer risk, the dotted lines around the solid line represent the poten-
tial range of welfare values that can occur from either the lower-risk
183 As the Irish Times reported:
Director of the Boyne Research Institute (BRI), Dr. Julianne Byrne, has said
that she finds the apparent delay in the introduction of mandatory folic acid
fortification "unreasonable," because the weight of scientific evidence
shows that it protects against most cases of neural tube defects (NTD) ....
She also questioned the validity of reported links between folic acid sup-
plementation and colorectal cancer. Alan Reilly, deputy chief executive of
the FSAI, said decisions about how to proceed with the fortification here
would be made on "rock-solid ground."
O'Connell, supra note 177.
184 See Medical News Today, Pharmion Corporation Announces FDA Ap-
proval of Vidaza NDA Supplement for IV Administration, http://www.medicalnews
today.com/articles/61849.php ("Azacitidine is the first of a new class of anti-cancer
compounds called epigenetic therapies . . . . Epigenetics refers to changes in the
regulation of gene expression. Epigenetic changes can silence gene expression and,
unlike DNA mutations, may be reversed by targeting the enzymes involved . ... The
epigenetic approach to cancer therapy is that rather than using molecules that kill both
normal and tumor cells, the silenced genes are reactivated through targeted epigenetic
therapy, re-establishing the cancer cell's natural mechanisms to control abnormal
growth.") (last visited May 3, 2010).
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voluntary fortification policy or the higher-risk mandatory fortifica-
tion policy. The voluntary fortification policy is characterized as a
lower-risk policy because it represents a smaller deviation from the
baseline. Given this, one would expect that both the upside benefit
(area between baseline and upper dotted line) and the downside risk
(area between the baseline and lower dotted line) for this policy to be
smaller than the mandatory fortification policy. Looking at the prob-
lem this way, how should a policymaker choose? If our bias is to be
risk-averse and avoid large downside risk, the voluntary fortification
option seems wise. However, the optimal search method would argue
for choosing the mandatory fortification option with its inherently
more variable outcomes. If one picks the voluntary option, one is
forgoing the opportunity of reaching the higher welfare points availa-
ble in the mandatory option; namely, very low NTD with no increase
in cancer. The avoidance of NTD will then be locked in for an indi-
vidual's lifetime. If one later learns more information to support that
the mandatory folic acid fortification policy causes an unacceptable
cancer risk and puts society way below the baseline, one can simply
reverse the policy and possibly reverse the cancer risk while still re-
taining the NTD prevention. Therefore, unlike the cost-benefit and
precautionary approach, the optimal search method provides a way
through this impasse and a clear policy choice.
Figure 1. Voluntary vs. Mandatory Folate Fortification
vs. Human Capabilities
Welfare WelfareLow NTD, low / Law NTD, ow
cancercancer
-' baseline baseBue
High NTD, High NT,high cancer hi cancer
1------------------------------
Time 
Time
Low Risk/Voluntary High Risk/Mandatory
While the optimal search method might provide a compelling
choice in the abstract, advocating a policy that admittedly might in-
crease the cancer risk for many citizens is not a politically satisfying
narrative. In other words, the optimal search method is a useful heu-
ristic under the conditions described above (reversibility, learning),
but it is less helpful when reversibility is not likely, and by itself, it
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provides a normatively shallow justification for distributing epigenetic
benefits on some and harms on others.
On the other hand, incorporating the CA into this discussion leads
one to a consistent and compelling normative framework for epigenet-
ic policymaking. Considering the cost-benefit and optimal search
methods, for reasons discussed above, one has to be wary about solely
relying on utilitarian calculations to guide one's regulatory choices.
Additionally, given the types of questions the CA asks policymakers
to address, paralysis may not ensue in the face of tough choices as
with the precautionary approach. Under the CA, not all epigenetic
risks are qualitatively equal as they raise very disparate normative
concerns. For instance, epigenetic risks associated with the develop-
ment of cognitive disabilities would trigger more concern under the
CA than epigenetic risks associated with the development of prostate
cancer. The priority would remain the same even if societal cost and
number of afflicted people was greater for prostate cancer compared
to cognitive disabilities.
The critical difference between the two is that the impact of cog-
nitive disabilities can severely limit the ability to make free choices
about one's life's direction. Thus, despite educational efforts or some
other remediation, a ceiling already has been placed on one's potential
opportunities. In contrast, prostate cancer represents qualitatively
different concerns. 185 It is estimated that 37,000 men in the United
States die annually from prostate cancer and that treatment costs ex-
ceed $5 billion per year.'86 The costs associated with this disease are
clearly substantial. However, incidence of prostate cancer is rare be-
fore the age of fifty-five, and most men who have prostate cancer die
with it, not from it. 187 In fact, the National Cancer Institute estimates
that over half of all men in the United States will have some cancer in
their prostate glands by the age of eighty.188 Viewed another way,
while prostate cancer is definitely a serious and costly disease on a
societal and individual level, it is not the type of impairment that de-
prives a person of most life opportunities or free choice, which are
185 The intent of this example is not to minimize the pain and suffering of
prostate cancer victims and their families. Rather, the intent is to show that even for
such a serious disease, the CA prompts us to ask different questions than a utilitarian
approach.
186 This places prostate cancer among the top three most costly cancers to
treat, along with lung and breast cancer.
187 NAT'L CANCER INST., U.S. DEP'T OF HEALTH & HUMAN SERVS.,
UNDERSTANDING PROSTATE CHANGES: A HEALTH GUIDE FOR MEN 17 (2009),
http://www.cancer.gov/PDF/4dbal 3db-81 fb-4d8d-9c2d-dOcOOaO48f57/prostate
booklet.pdf.
188 id.
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prime concerns of the CA. Returning to the Ireland folic acid debate,
combining the optimal search method approach with the CA provides
policymakers with both a persuasive technocratic (optimal search) and
principled normative (CA) argument to push forward with mandatory
fortification of flour with folic acid.
Justice concerns are paramount to the CA, especially considera-
tions of equitable distribution of harms and benefits. The CA incorpo-
rates the Kantian principle of treating every person as an end in
herself. Thus, one might argue that a mandatory fortification policy
violates the CA because putative infants seemingly gain a benefit at
the expense of the elderly (if the harmful effects of surplus folic acid
are not reversible for the elderly). However, viewed from a holistic
life-cycle perspective, infants will eventually become old so they are
sharing in the burdens of this policy as well. Therefore, if nobody is
selected for differential epigenetic risk during a lifetime, equitable
concerns are mitigated as the risk would be diffuse and spread nearly
evenly across society. One's concern would then turn to whether hav-
ing this particular consumer good, with its attendant epigenetic risk,
either enhanced or limited our capabilities. If a particular epigenetic
risk, however, was non-randomly distributed among the population,
then the CA would be violated. For example, if an epigenetic pollu-
tant was spread locally from a certain type of industrial plant located
near lower-income or minority neighborhoods (a situation which is
exceedingly common), the CA would be concerned that society was
imposing such costs in a discriminatory manner - even if this activity
provided a tremendous amount of benefit to most members of society.
Returning to the Irish folic acid debate, the mandatory fortification
option satisfies the justice concerns of the CA because even if this
policy leads to increased cancer risk, no individuals or groups are be-
ing singled out to shoulder this burden disproportionately.
VI. ADAPTIVE KNOWLEDGE FORCING
REGULATORY FRAMEWORK
There is a clear logic to Judge Posner's dictum that "law lags
science; it does not lead it," in the context of courtroom proceed-
ings. 89 Society would probably not benefit from generalist jurists de
facto creating scientific policies from the bench and in essence arbitra-
rily determining the legitimacy of competing scientific theories.
However, does it follow that policymakers must also lag behind until
189 Rosen v. Ciba-Geigy Corp., 78 F.3d 316, 319 (7th Cir. 1996) ("But the
courtroom is not the place for scientific guesswork, even of the inspired sort. Law
lags science; it does not lead it.").
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scientific research develops definitive answers? This appears to be
the conclusion of those who favor a "rationalist" approach based on
quantifiable costs and benefits. Their implicit view is that science will
tell society the correct course in due time. However, science is not an
anthropomorphic being; it does not "tell" anything. Scientific data
has no meaning until one interprets it, and such interpretations are
inevitably packed with qualitative judgments. For instance, "relative
risk" is an epidemiological ratio that represents probability of an event
(e.g., disease) occurring to a group exposed to an agent versus a non-
exposed control group. A relative risk of 1.0 means there is no differ-
ence in observed risk between the exposed and control group.' 90 A
relative risk of 2.0 indicates a doubling of observed risk in the ex-
posed group, meaning that "the [exposure] agent is responsible for an
equal number of cases of disease as all other background causes."'91
By legal and medical convention, a relative risk of at least 2.0 is con-
sidered the threshold where science tells us there is "proof' of causa-
tion. 192 But what if the relative risk is 1.9? Does this mean that
science is telling us we do not have to worry about this particular sub-
stance? Considering the myriad of chemical agents one is exposed to
on a daily basis along with the increasing recognition of the multi-
factorial nature of disease causation, the less likely any medical expert
is able to demonstrate the "magic" relative risk of 2.0 for contracting a
disease based upon any one particular chemical exposure.
Of course, in the realm of policymaking for public health and
safety, scientific research should guide our decisions. However, one
cannot lose sight of the fact that many of the scientific norms
that have developed regarding causation (e.g., relative risk of 2.0 at a
ninety-five percent confidence interval) are somewhat arbitrary, and
failing to meet these thresholds should not be taken as "rational bar-
riers" to policies or interventions. Further, if one takes a laissez-faire
attitude towards manufacturers developing scientific data about the
190 FED. JUDICIAL CTR., REFERENCE MANUAL ON SCIENTIFIC EVIDENCE 384
(2d. ed. 2000).
19' Id. (discussing the relative risk: "The threshold for concluding that an
agent was more likely than not the cause of an individual's disease is a relative risk
greater than 2.0. Recall that a relative risk of 1.0 means that the agent has no effect on
the incidence of disease. When the relative risk reaches 2.0, the agent is responsible
for an equal number of cases of disease as all other background causes. Thus, a rela-
tive risk of 2.0 (with certain qualifications noted below) implies a 50 percent likelih-
ood that an exposed individual's disease was caused by the agent. A relative risk
greater than 2.0 would permit an inference that an individual plaintiffs disease was
more likely than not caused by the implicated agent. A substantial number of courts
in a variety of toxic substances cases have accepted this reasoning.").
192 id.
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safety of their products, does this not mean regulations are held hos-
tage to one's willful ignorance? Instead of having policies that either
lag behind science or try to lead it, why not have a policy that actively
pushes scientific knowledge forward? In other words, regulators
should advocate a policy that forces knowledge generation from man-
ufacturers.
A major barrier for enacting a regulatory system to control epige-
netic harm is lack of specific epigenetic risk profiles for almost all
manufactured products and activities. So how can we overcome this
ignorance? As discussed above, with a few exceptions like regula-
tions stemming from the FDCA, FIFRA, and clean air and water
bills, 93 corporations are usually not required to provide information
on the impacts of their products or activities. The predominant regu-
latory scheme of cost-benefit analysis in the United States has defacto
placed the cost of uncertainty on the public and has granted firms the
right to externalize harm when the public is unable to demonstrate that
the alleged harm outweighs the benefit. This allocation of burden
related to the knowledge of harms does not make sense when one
knows that producers possess superior information and ability to gen-
erate such information.194
Politically it is not viable, nor does it seem appropriate, to place
the burden of general epigenetic safety research on manufacturers.
Much the same way the government subsidized general knowledge
involving computers, the Internet, and the Human Genome Project, it
seems that the United States and other developed nations have an
imperative to finance research in the area of epigenetics. To help pri-
oritize which general classes of substances should be focused on, a
new epigenetics agency or division, similar to the Agency for Toxic
Substances and Disease Registry (ATSDR), can be established. The
federal government established the ATSDR under the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980
(CERCLA) and tasked it with assessing public health and safety is-
sues stemming from hazardous substances and toxic waste sites.19 5
193 For example, under California's Safe Drinking Water and Toxic Enforce-
ment Act (1986), where there is evidence that certain toxins can cause cancer or
harmful reproductive effects, the burden is not on the state regulatory agency to prove
that the substances are harmful, but rather on the industry to prove that the chemicals
pose, "no significant risk (for cancer), or [is] sufficiently below the no observable
effect level (reproductive toxins)." Garrett, supra note 116, at 545.
'94 Id. at 5 57.
19 The Agency for Toxic Substances and Disease Registry (A TSDR): Prob-
lems in the Past, Potential for the Future?: Hearing Before the H.R. Subcomm on
Investigations & Oversight, Mar. 12, 2009, http://democrats.science.house.gov/
Media/File/Commdocs/hearings/2009/Oversight/12mar/HearingCharter.pdf.
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However, the House Science Committee, Subcommittee on Investiga-
tions and Oversight, issued a recent report highly critical of the
ATSDR:
Time and time again ATSDR appears to avoid clearly and di-
rectly confronting the most obvious toxic culprits that harm
the health of local communities throughout the nation. In-
stead, they deny, delay, minimize, trivialize or ignore legiti-
mate concerns and health considerations of local communities
and well respected scientists and medical professionals. 19 6
Further, Committee Chairman, Congressman Brad Miller accused the
ATSDR of practicing bad science and having, "a keenness to please
industries and government agencies that prefer to minimize public
health consequences of environmental exposures."l 97
Agency capture and bad science is always a concern with gov-
ernment regulators. One possible solution is to invite early involve-
ment of the Institute of Medicine (IOM) and task it with forming a
panel of experts to evaluate the nature of epigenetic risk and to help
set priorities upon which substance classes to focus. 198 The IOM has
proven to be a credible source of advice, utilizing doctors, statisti-
cians, economists, and other researchers to establish scientific and
policy consensus on complex issues such as Agent Orange, breast
implants, and vaccine injuries.199 Further, since the IOM is outside of
196 Id
197 Rita Beamish, Agency to Improve Reporting of Neighborhood Toxics,
ASSOCIATED PRESS, Mar. 12, 2009, http://abcnews.go.com/Politics/wireStory?id
=7070328.
198 John Graham, former head of the Office of Information Regulatory Affairs
(OIRA) under President George W. Bush, advances the argument of using the IOM to
help set regulatory agencies' priorities. See Graham, supra note 7, 530 ("Justice
Stephen Breyer has suggested that a small cadre of lifesaving specialists be housed
inside the Executive Office of the President and granted vast priority-setting powers.
Professor Sunstein has advocated that OIRA become more involved in priority set-
ting. Although these ideas are certainly worth exploring, I believe that part of the
solution must come from a credible source outside of government [referring to the
IOM].") Inst. of Med., About the IOM, http://www.iom.edu/About-IOM.aspx (last
visited May 3, 2010) (describing the IOM mission as follows: "The Institute of Medi-
cine serves as adviser to the nation to improve health. Established in 1970 as the
health arm of the National Academy of Sciences, the Institute of Medicine is a non-
profit organization that works outside of government to provide unbiased and authori-
tative advice to decision makers and the public.").
199 During private practice as a products liability litigator and as an intern at
the Federal Judicial Center, I dealt with Agent Orange, breast implants, and vaccine
injury litigation, and frequently relied on IOM reports as objective, scientific consen-
sus statements on these topics.
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government and vets its experts for issue neutrality (meaning that the
experts are not involved with industry or litigation on a particular is-
sue), the IOM is sheltered from political and industry pressures.200
The IOM's recommendations can then help set out the initial tasks of
this new epigenetic agency.
Once researchers have developed a core of epigenetic knowledge
that allows them to accurately predict the types and probabilities of
certain diseases related to epigenetic mechanisms, it seems entirely
appropriate to shift the burden of providing specific epigenetic safety
data onto manufacturers. The onus of uncertain risk should not be
placed on diffuse consumers who are in no position to generate such
information. In the context of epigenetic harm, as the scientific com-
munity continually learn more about this process and particularized
risks, administrative agencies can adjust the intensity of regulations
based upon the particular knowledge level of any given substance. As
discussed below, the framework I suggest would have four different
levels of regulations that are adaptive to researchers' understanding of
epigenetic harm and its effect on human health and capabilities: (i)
disclosure; (ii) labeling; (iii) epigenetic tax and permit system; and
(iv) restricted uses or total ban. By adopting an iterative and sliding-
scale approach, this framework respects the need to ground regula-
tions upon scientific findings, but rejects a binary approach that
imagines only action or inaction based upon the presence or absence
of scientific proof.
200 See Inst. of Med., supra note 198.
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Figure 2. Adaptive Regulatory Framework
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A. Level 1: Disclosure Standard
Paracelsus was a chemist and physician in the 1500s and is consi-
dered the father of toxicology, the study of poisons. He is often
quoted for the dictum, "dose makes the poison," which remains one of
the bedrock principles of toxicology. In other words, any substances,
even those seen as innocuous, can be harmful in a great enough dose.
Thus, fresh water can be poisonous in large enough doses, causing
seizures and even death.2 0 1 Going back to Jirtle's agouti mice expe-
riment (discussed supra), the dose of folate rich foods proved to be
very beneficial to those particular mice, turning off the effect of a
harmful gene. However, recalling the Ireland folate supplementation
debate, the fear is that while a little folate might be beneficial, too
much of this substance might turn off helpful tumor suppressor genes
201 See Melissa Conrad Stappler, Hyponatremia (Low Blood Sodium),
http://www.medicinenet.com/hyponatremia/article.htm (last visited May 3, 2010).
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and increase the risk of certain cancers - hence, dose determines
whether the substance is helpful or harmful.
Therefore, an important threshold question, regarding chemicals
and consumer products, is whether such substances cause significant
epigenetic markings or modifications. The ability of a substance to
cause epigenetic marking is not an indication of harm per se, and
might even prove beneficial, as in the agouti experiment. However,
for an individual, it would be important to know if one was accumu-
lating too great a dose of any particular type of epigenetic marking
from an overall combination of substances. In the same way that an
Ames test provides an inexpensive and quick way to assay whether a
substance has mutagenic potential (and hence cancer-causing poten-
tial),202 it is not difficult to imagine that a similar testing model can be
developed to measure the potential of a substance to cause epigenetic
modifications. Positive evidence of epigenetic modifications could
then indicate the need for more robust testing in animal models.
Under my proposal, the burden to demonstrate the extent of epi-
genetic modifications a chemical substance causes would be placed on
manufacturers. This information would then be required to be
disclosed to the appropriate government regulatory agency. 203 This
regulatory approach would be consonant with the EU's regulation of
manufactured chemicals, the Registration, Evaluation, Authorisation
and Restriction of Chemicals (REACH), which was adopted in
December 2006.204 The goal of REACH is to "provide a high level of
protection of human health and the environment through earlier and
improved identification of the inherent properties of chemical sub-
202 The Ames test was developed in the 1950's by University of California
Berkeley researcher Bruce Ames. The test uses a strain of salmonella bacteria that
can be grown cheaply, yielding results in only one day. Bruce N. Ames et al., An
Improved Bacterial Test System for the Detection and Classification of Mutagens and
Carcinogens, 70 PROC. NAT'L ACAD. Sa. 782 (1973).
203 Rather than relying on manufacturers own tests which might be subject to
bias or obfuscation, the government can require testing be done by certified labs
which are audited by the government. As illustrated by the Georgia peanut scandal,
relying on private testing facilities that are not overseen by the government can be
problematic as manufacturers might direct their business to labs that will give them
favorable results, thus creating incentives for labs to perhaps have lax standards if
they are not subject to oversight. Another tactic used by the offending peanut manu-
facturer was to not report repeated test results that showed presence of salmonella and
only report tests that were negative. See Lyndsey Layton, Peanut Processor Kno-
wingly Sold Tainted Products, WASH. POST, Jan. 28, 2009, at Al. A regulation that
took away discretion from manufacturers from selectively reporting test results and
made disclosure of all tests by certified labs to the government mandatory could solve
this "cherry-picking" problem.
204 See generally Council Regulation 1907/2006, 2006 O.J. (L 396) 1 (EC).
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stances."205 The mantra of REACH is "no data, no market," meaning
all chemicals must be registered in order to be merchantable in the
EU.206 REACH not only targets substances in isolation, but also in
compounds and articles containing chemical substances where it is
foreseeable that such substances will be released during normal
usage.2 07 What if multiple companies make the same chemical - do
these companies need duplicative laboratory and animal tests?
REACH allows for substance information exchange forums (SIEF) to
be set up so that companies can voluntarily share data on identical
substances. In the case of animal testing, REACH mandates informa-
tion-sharing in order to reduce redundancy of these tests.208 As
discussed above, it is clear that U.S. regulatory agencies have the po-
tential legal authority to shift the burden of testing onto manufacturers
in a regime similar to REACH and could mandate the generation of
basic epigenetic information.
Once an epigenetic profile of a substance is generated, should this
information be required on a product's label? The appropriate answer
seems to be "no." In the abstract, this information is likely not useful
to the average consumer and might only cause fear and confusion in
consumers should they automatically assume that epigenetic markings
are per se harmful. 20 9 This information is most helpful and important
to regulatory agencies for consideration of how much follow-up test-
ing should be done on particular substances. Analogizing to the Ames
test, a positive result on this assay does not mean that a substance is
necessarily carcinogenic and a negative test does not mean that a sub-
stance is not carcinogenic. However, the Ames test has proven to be a
helpful screen in identifying potential carcinogens which would indi-
cate the need for further in-depth testing. The epigenetic equivalent of
the Ames test should be viewed in the same manner.
The case for regulating manufactured chemicals which cause epi-
genetic changes seems clear, but what about "natural" substances like
205 Isabelle Laborde, REACH: The New European Union Chemicals Regula-
tions, 23 NAT. RESOURCES & ENV'T 63, 63 (2009).
206 id.
207 Id. at 63-64. This regulation also applies to chemicals manufactured for
export only to rebut charges that this is a protectionist scheme by the EU. For US
manufacturers, falling behind this standard could prove costly and limit their overall
market access, in the same manner that falling behind higher fuel standards in the rest
of the world crippled the competitiveness of American car manufacturers.
20. Id. at 64.208
2 As behavioral scientists have noted, providing more information does not
always lead to better understanding by the recipient as the individual might expe-
rience "cognitive dissonance," or difficulty in incorporating new information that
does not correspond to their previous understanding.
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food products? Should regulators punt on epigenetic regulation of
these substances and only focus on synthetic chemicals? As Sunstein
points out in his critique of the precautionary principle, the reason
many view artificial or processed substances as being less safe than
natural substances is due to the cognitive bias of believing in the "be-
nevolence of nature." 210 However, we know that many natural prod-
ucts can be harmful; for example, tuna may harm pregnant women
(due to high mercury content) and natural licorice can cause severe
hypertension and potassium deficiency.
One response might be that traditional food products have become
"traditional" through a natural process of empiricism. That is, for
thousands of years, humans have been figuring out what is safe and
not safe to ingest or put on their body by trial and error. Thus, an un-
derlying logic justifies trusting the safety of natural products as op-
posed to newer synthetic products. However, going back to Jirtle's
agouti mice experiment, the dramatic change in epigenetic program-
ming that he accomplished was not through administration of complex
synthetic compounds, but through simple vegetables like onions,
beets, and leafy vegetables. Therefore, there is a serious rationale to
generate more knowledge about the epigenetic effects of everyday
foodstuffs. The question then becomes "who should be responsible
for generating epigenetic safety information regarding food prod-
ucts?" Should a small family farm have the same burden placed on it
as industrial food giants like Con-Agra or Archer Daniels Midland?
Here it seems more efficient and practical to have the U.S. Depart-
ment of Agriculture perform testing on bulk distributors of fruits, veg-
etables, grains, and meats, and to exempt smaller farms from such
211
requirements. However, for processed or packaged food compa-
nies, it is rational to place this burden on them, as Company A might
process their creamed corn in a completely different manner than
Company B. This would add a de minimis burden, as food companies
already are required to test the general safety of their products.
210 See Sunstein, supra note 167.
211 It is common for public health regulations, such as nutritional labeling
requirements for restaurants, to distinguish between large and small business opera-
tors. See New York State Rest. Ass'n v. New York City Bd. of Health 556 F.3d
114, 121 (2d Cir. 2009) (The court upheld state law mandating the chain restaurants
provide nutritional information to customers. The law did not apply to smaller, non-
chain restaurants.).
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B. Level 2: Labeling Standard
Once researchers can publish data in peer-reviewed journals that a
substance can cause epigenetic harm in something more robust than a
simple petri dish assay, such as in more than one species of laboratory
animal, then it seems warranted for an epigenetic risk agency to re-
quire labeling of their products to state this result. The labeling
statement can be as simple as "Animal Studies have demonstrated
evidence of epigenetic harm caused by this product." If manufactur-
ers can reference or conduct independent human epidemiological stu-
dies that do not demonstrate evidence of harm, then manufacturers
could add the truthful disclaimer that evidence of harm in human
studies has not yet been established. The intent of allowing this dis-
claimer is that it provides manufacturers with an incentive to fund
independent research on human populations.
One response might be that, even without the human studies dis-
claimer, labels are an inherently weak form of regulation, and allow-
ing disclaimers makes the labels even weaker.2 12 However, the virtue
of standards one and two under this framework is that they intention-
ally do not exert a very powerful effect. Stronger measures that could
drastically reduce or eliminate the viability of products would be dif-
ficult to justify given that the evidence of harm contemplated to trig-
ger these measures is also comparatively weak. So what is the point
of having intentionally weak regulations? The value of such regula-
tions is the provision of early notice to manufacturers and end-users
that they might want to start considering the development or use of
alternative products. This scheme should mitigate the "no suitable
alternative" problem highlighted in the EPA's attempt to ban asbes-
tos. 213
C. Level 3: Epigenetic Tax and Permit System to Protect
Human Capabilities
The tort system is predictably ill-suited to regulate epigenetic
harm, and a purely utilitarian regulatory scheme fails to address qua-
litative differences in epigenetic harm. So how can one practically
address the problem of epigenetic risk? Under Nussbaum's concep-
tion of the CA, the general way to formulate policy questions is to ask
what one values and seek to protect through collective action:
212 See John Abramson, The Reliability of Our Medical Knowledge as a
Product ofIndustry Relationships, 35 HOFSTRA L. REv. 691, 697-98 (2006).
213 See Corrosion Proof Fittings v. EPA, 947 F.2d 1201, 1215-17 (5th Cir.
1991).
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In all cases, however, a political scheme will not realize the
goals of the CA unless it identifies a core group of entitle-
ments that deserve to be protected stably, regardless of major-
ity whim, and then asks carefully whether people face unequal
obstacles to the enjoyment of their basic entitlements, devot-
ing particular attention to traditionally disadvantaged
gUS214groups.21
As Nussbaum explains, the CA suggests that the government make a
"short list" of individual entitlements or capabilities that will be pro-
tected equally for all citizens. 2 15 Ensuring adequate education, health-
care, and political liberty are typical entitlements put forth by CA pro-
ponents. Using this list, one can prioritize which epigenetic harms
pose the greatest threat to developing our human capabilities and
which harms are inequitably distributed. Then one can attach greater
penalties (taxes) or barriers (permits) to producers of epigenetic harm
that undermines our human capabilities or to producers of harm that
disparately impacts some discrete group. In this way, an epigenetic
regulatory agency can calibrate a tax and permit system to reflect
qualitative decisions to protect capabilities in an equitable and
non-arbitrary fashion.
The government can set up a permit scheme based upon a manu-
facturer's ability to disclose epigenetic risk data about its products or
activities. Thus, development and disclosure of epigenetic safety
information will allow a company to sell their goods in their market-
place or operate their factories. While industry might protest vigo-
rously, a permit scheme for consumer goods, similar to prescription
drugs receiving FDA market approval, can convey significant benefit
to a manufacturer, certifying the product for the marketplace and
erecting barriers to less sophisticated or responsible competitors who
take shortcuts.216 An important consideration is the duration of the
214 Nussbaum, supra note 12, at 57.
215 Id. at 20 ("The CA, by contrast, is quite abstemious: it identifies a very
short list of core entitlements that should be secured to all citizens as basic entitle-
ments of ajust society. Beyond that short list, the CA does not make sweeping claims
about the overall good. It allows people to make their own choice based on their
different views of the good life. Moreover, since the core entitlements are understood
as capabilities, rather than as actual functions or actions, giving one of them to a
person does not require him or her to use it.").
216 Loretta Chao, More Firms Tied to Tainted Formula: China Officials Say
Industrial Chemical was in Baby Food, WALL ST. J., Sept. 17, 2008, at A23 (describ-
ing recent scandal involving food products from China adulterated with melamine);
Austin Ramzy, China's Melamine Woes Likely to Get Worse, TIME, Nov. 4, 2008,
http://www.time.com/time/world/article/0,8599,1856168,00.html; U.S. Food & Drug
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permit. Since scientific knowledge can fluctuate rapidly as new data
is gathered, a permit's time span should be linked to the progression
of knowledge within the field. For epigenetics, this might mean a
default permit for ten years, which would nevertheless allow the per-
mit agency to call for a special review in light of new information,
especially if a firm has not disclosed or neglected to perform addition-
al research within a decade time frame.
Epigenetic taxes can be structured to create incentives for firms to
compete with each other on the development of risk information. For
example, if Company A and Company B make the same product X,
but Company A develops more epigenetic risk information on X, it
could receive a discounted tax assessment compared to Company B.
In addition to incentivizing research, this strategy addresses free rider
concerns related to which parties should bear the cost of safety testing.
Safety information exchanges, as envisioned by the EU and its
REACH legislation, can also address efficiency concerns related to
217
redundant testing.
D. Level 4: Restricted Uses and Outright Ban
If scientific studies ultimately prove that certain substances cause
severe epigenetic harms that are not reversible, the appropriate regula-
tory action would be to ban such substances from general use. Once
again, under a CA focus, harms that have greater deleterious effects
on individuals' abilities to make free choices or that limit the scope of
their life options are considered to be relatively more severe than oth-
er harms. Prioritizing epigenetic harms is important, because a ban on
one substance predictably could lead to the use of risky substitutes. 218
Thus, under the framework I propose, regulatory agencies would need
to rank the epigenetic harms caused by substances, especially when
substitution of one substance for another is likely.
Given the strength of this regulatory measure, it is appropriate to
demand that the corresponding level of scientific knowledge be equal-
ly strong: reproducible, peer-reviewed scientific studies demonstrating
a significant increase in epigenetic risk. As discussed above, I hesi-
tate to suggest a relative risk threshold of 2.0 as the necessary thre-
Admin., Melamine Contamination in China, available at http://www.fda.gov/
NewsEvents/PublicHealthFocus/ucml 79005.htm (last visited May 3, 2010).
217 See Laborde, supra note 205, at 63.
218 See Cass R. Sunstein, Health-Health Tradeoffs, 63 U. CHI. L. REv. 1533,
1541-42 (1996) (arguing that regulatory bans can lead to risky substitutes). Of
course, Sunstein would likely calculate the tradeoffs in a different manner as he is a
strong proponent of cost-benefit analysis.
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shold for a regulatory ban. For example, if the relative risk of a sub-
stance causing epigenetic developmental defects is only 1.9, I think it
should be within an agency's discretion to ban such a substance. The
insistence on reproducible and peer-reviewed data is distinguishable
because one needs to know if any measured risk is legitimate and not
due to chance or poor scientific methodology. In contrast, deciding
on whether to enact a regulatory ban based upon a 1.9 or 2.0 relative
risk is a quantitative, not qualitative, decision.
The issue of paternalism versus libertarianism in the banning of
substances is especially thorny when epigenetics enters the equation.
For example, adopting the libertarian view, one can argue that so long
as individuals are given notice that a certain substance is harmful, they
should be allowed the freedom to choose whether they want to risk
exposure. However, given the multi-generational persistence of epi-
genetic markings, notice and choice are necessarily absent for future
generations suffering from epigenetic risk acquired before they even
came into existence. This in turn raises the issue of generational jus-
tice and the extent to which the present generation is held responsible
for risks that will be passed on to future generations. As in the debate
regarding climate change regulations, talking about protecting future
generations that would not come to be even during our own lifetime
makes the case for taking action more difficult and attenuated. How-
ever, with epigenetic risk as with catastrophic climate change, one is
talking about taking decisive action against harms that might affect
our generation directly as well as generations born during our lifetime.
CONCLUSION
This article explores the meaning of epigenetic risk and why ad-
dressing it from a legal and policy perspective is critical. Epigenetics
is a rapidly evolving field, and no doubt researchers will develop more
knowledge about how one acquires and pass on epigenetic marks,
about the impact such marks on human disease and development, and
about the extent to which medicine can manipulate or modify the epi-
genetic effects. Viewing the issue from the CA framework, the im-
perative for addressing epigenetic risk is not merely the biological or
medical concerns involved, but more generally the underlying fairness
and justice of the American social contract. How one develops men-
tally or physically has a tremendous impact upon one's set of capabili-
ties and hence the ability to choose a life of one's own making. Of
course, there is no such thing as absolute freedom from biological or
social constraints - some people will innately be more physically fit
or intelligent than others. However, with epigenetics, one considers
how much of these biological constraints are "innate" as opposed to
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externally manufactured. The CA prompts one to ask questions such
as: what impact do particular epigenetic risks have on one's ability to
exercise free choices, are these risks avoidable, and how are such risks
distributed across society?2 19
Addressing epigenetic risk poses some of the same challenges as
addressing global climate change. The more variables and complex
interactions that must be accounted for, the less likely scientific re-
searchers will establish "conclusive proof" of cause and effect or neat-
ly quantify the costs and benefits of an action. Additionally, as with
global climate change, scientific uncertainty will be used as a basis for
undermining the legitimacy of measures and regulations aimed at re-
ducing epigenetic risk. The adaptive framework I propose holds that
the growing evidence that particular environmental exposures cause
epigenetic risks cannot be ignored and that overall uncertainty about
epigenetics should first result in knowledge-generating policies rather
than inaction. As data regarding epigenetic risks accrues, this frame-
work accounts for such learning and enables the intensity of any epi-
genetic-based regulation to be rationally tied to existing knowledge.
The stakes are high, given evidence that potentially avoidable epige-
netic risks are not only causing disease, but also harming the capabili-
ties writ large of present and future generations.
219 The epigenetic effects of social interactions (e.g., parent-child bonding,
bullying, discrimination) is a fascinating area of inquiry, but as stated in the Introduc-
tion, is outside the scope of this article. Obviously, regulating social interactions
raises quite different jurisprudential and political concerns than regulating exposures
to chemical substances.
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